AU767970B2 - Anionic or cationic dendrimer antimicrobial or antiparasitic compositions - Google Patents

Description

WO 00/15240 PCT/AU99/00763 -1- ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS FIELD OF THE INVENTION This invention relates to inhibition of microbial and parasitic agents, and in particular it relates to the use of dendrimers as inhibitors of infection of human and nonhuman animal patients by pathogens such as bacteria, fungi or parasites.

BACKGROUND OF THE INVENTION Dendrimers are 3-dimensional polymeric materials of low polydispersity which are characterised by a large number of surface terminal groups. In addition, the manner in which these materials are prepared allows tight control over the size, shape, and number and type of surface groups. Dendritic materials have several features that are useful for use as therapeutic materials: fixed shape which presents a large and defined surface with which to interact with biological surfaces and receptors; and the large number of terminal groups allow for multiple interactions with the biological targets.

International Patent Applications No. PCT/AU95/00350 (WO 95/34595) and PCT/AU97/00447 (WO 98/03573) disclose dendrimers such as a polyamidoamine or polylysine dendrimers having a plurality of terminal groups, wherein at least one of the terminal groups has an anionic- or cationic-containing moiety bonded or linked thereto.

The contents of these published International patent applications are incorporated herein by reference.

The present invention provides the use of dendritic polymers in the inhibition of microbial agents including bacterial and fungal pathogens, and parasitic agents.

WO 00/15240 PCT/AU99/00763 -2- SUMMARY OF THE INVENTION According to the present invention, there is provided a method of prophylactic or therapeutic inhibition of a microbial or parasitic agent in a human or non-human animal patient, which comprises administration to the patient of an effective amount of a dendrimer having a plurality of terminal groups wherein at least one of said terminal groups has an anionic- or cationic-containing moiety bonded or linked thereto.

Particularly preferred compounds for use in the method of the present invention are dendrimers having sulfonic acid-containing moieties, carboxylic acid-containing moieties, phosphoric or phosphonic acid-containing moieties, boronic acid-containing moieties, neuraminic or sialic acid-containing moieties or moieties containing neuraminic or sialic acid; primary, secondary, tertiary or quaternary amino-containing moieties, pyridinium-containing moieties; guanidinium-containing moieties; amidinium-containing moieties; phenol-containing moieties; heterocycles possessing acidic or basic hydrogens; zwitterionic-containing moieties; or mixtures of the above moieties, linked to terminal groups thereof.

The compounds used in the method of this invention are referred to herein as polyionic dendrimers, and this term is used throughout this specification to include not only the dendrimers per se, but also their pharmaceutically or veterinarily acceptable salts, for example the alkaline metal or alkaline earth metal salts such as the sodium, potassium or calcium salts as well as pharmaceutically acceptable anions such as fluoride, chloride, bromide, iodide, citrate, acetate, p-toluene sulfonate and the like.

DETAILED DESCRIPTION OF THE INVENTION Preferred compounds used in accordance with the present invention include polyionic dendrimers of the general formula I: WO 00/15240 PCT/AU99/00763 -3- A A Z is an interior branching unit; A

A

A A A A A A A wherein: I is an initiator core; Z is an interior branching unit; n is an integer which represents the number of generations of the dendrimer; and A is an anionic- or cationic-containing moiety which may be linked to interior branching unit Z through an optional linking group X.

Dendrimers are macromolecular highly branched compounds formed by reiterative reaction sequences starting from an initial core molecule with successive layers or stages being added in successive "generations" to build up a three-dimensional, highly ordered polymeric compound. Dendrimers are characterised by the following features: I an initator core which may have one or more reactive sites and be point-like or of significant size so as to effect the final topology of the dendrimer; ii layers of branched repeating units attached to the initiator core; iii functional terminal groups (such as moieties A) attached to the surface of the dendrimer, optionally through linking groups (such as linking groups The present invention uses dendritic structures as frameworks for the attachment of ionic moieties; the invention is not limited to the spherical WO 00/15240 PCT/AU99/00763 -4dendrimers described in detail herein but can be based on any dendritic structure. The variety of dendrimers in both shape and constitution are well known to persons skilled in the art.

The preparation of dendrimers is well known, and is described by way of example in U.S. Patents Nos. 4289872 and 4410688 (describing dendrimers based on layers of lysine units), as well as U.S. Patents Nos. 4,507,466, 4,558,120, 4,568,737 and 4,587,329 (describing dendrimers based on other units including polyamidoamine or PAMAM dendrimers). The dendrimers disclosed in these US patents are described as being suitable for uses such as surface modifying agents, as metal chelating agents, as demulsifiers or oil/water emulsions, wet strength agents in the manufacture of paper, and as agents for modifying viscosity in aqueous formulations such as paints. It is also suggested in U.S.

Patents Nos. 4,289,872 and 4,410,688 that the dendrimers based on lysine units can be used as substrates for the preparation of pharmaceutical dosages.

International Patent Publications Nos. WO 88/01178, WO 88/01179 and WO 88/01180 disclose conjugates in which a dendrimer is conjugated or associated with another material such as a carried pharmaceutical or agricultural material. In addition, International Patent Publication No. WO 95/24221 discloses dendritic polymer conjugates composed of at least one dendrimer in association with a carrier material which can be a biological response modifier, and optionally a target director. These patent publications together with the U.S. patents mentioned above contain a broad disclosure of various dendrimers and processes for the preparation thereof, and the disclosure of each of these publications is incorporated herein by reference.

The term "dendrimer" as used herein is to be understood in its broadest sense, and to include within its scope all forms and compositions of these dendrimers as disclosed in Patent Publications Nos. WO 88/01178, WO 88/01179 and WO 88/01180. The term also includes linked or bridged dendrimers as disclosed in these patent publications.

WO 00/15240 PCT/AU99/00763 The preferred dendrimers of the present invention comprise a polyvalent core covalently bonded to at least two dendritic branches, and preferably extend through at least two generations. Particularly preferred dendrimers are polyamidoamine (PAMAM) dendrimers, PAMAM (EDA) dendrimers, poly(Propyleneimine) (PPI) dendrimers and polylysine dendrimers.

In accordance with the present invention, at least one, and preferably a substantial number, of the terminal groups on the surface of the dendrimer has an anionic- or cationiccontaining moiety covalently bonded thereto. The branches of the dendrimer may terminate in amino groups or other functional reactive groups such as OH, SH, or the like, which subsequently can be reacted with the anionic or cationic moieties. Where the terminal groups of the dendrimer are amine groups, the anionic- or cationic-containing moiety may be linked to the dendrimer by a variety of functional groups including amide and thiourea linkages. Preferred anionic- or cationic-containing moieties which may be bonded to the terminal groups of the dendrimer include sulfonic acid-containing moieties, carboxylic acidcontaining moieties (including neuraminic and sialic acid-containing moieties and modified neuraminic and sialic acid-containing moieties), boronic acid-containing moieties, phosphoric and phosphonic acid-containing moieties (including esterified phosphoric and phosphonic acid-containing moieties) and primary, secondary, tertiary or quaternary amino-containing moieties, pyridinium-containing moieties; guanidinium-containing moieties; amidinium-containing moieties; phenol-containing moieties; heterocycles possessing acidic or basic hydrogens; zwitterionic-containing moieties; or mixtures of the above moieties.

Suitable anionic- and cationic-containing moieties which may be bonded or linked to the amino or other terminal groups include, by way of example, the following groups (in which n is zero or a positive integer, more particularly n is zero or an integer of from 1 to

NH(CH

z )nSO" (CH 2 )nSO" Ar(SOj)n

CH

2 CH(SO)COOH CH(S0 3

)CH

2 COOH ArX(CH 2 )nSO- X OS, NH

(CH

2 ),NM6 3 -Ar(NMe 3 )n -ArCH 2 NMe 3 WO 00/15240 WO 0015240PCT/AU99/00763 -6-

H

0 x2K,

SO

3 Na 0

H

0YOO

HA

HA

y

SC

3 Na

S

HA

Na0 3 LS0 3 Na

S

HAk

SO

3 Na

S

HA

NaO 3 SIcxSO 3 Na NaO 3 S SO 3 Na 0

HA

SO

3 Na 0 S0 3 Na 0 S0 3 Na 0 S0 3 Na

~H

COOH

NH

0 AVK AMe 3 0*1

YMG

AM0 -ArXP(=O)(OR) 2 X=O, CH 2 CHF, CF 2 R=alkyl, aryl, H, Na.

-ArXP(=O)(R)(NR 2 R 3 X0=, CH 2 CHF, CF 2 Rl=alkyl, aryl, H, Na R 2 R 3 =alkyl, aryl

-AP(=O)(OR)

2 RalkyI, aryl, H, Na n=1-3

-AB(OH)

2 n=1-3 -AC0H], n=1 -3

S

HN"

PO(OEt) 2

S

HN/ 11 COONa

S

MN PO(OEt)(ONa)

S

HN PO(ONa) 2

S

HN PO(ONa) 2

S

HN NaOOC b COONa WO 00/15240 WO 00/ 5240PCT/AU99/00763 S S

S

HN Hk HNJLN PO(ONa) 2 PO(OEt)(QNa) PO(OEt) 2 HN

S

0.PO(ONa) 2 0 PO(OEt)(ONa) 0.PO(OEt) 2

,COOH

C2

NH

NH

2

-NI

NH

S N >N

NH

_N

CF

3

-COCN

H

-N-R-C00- -N+-R-S0 3

\OH

R= alkyl or arylalkyl; R 2

R

3 (which may be same or different) alkyl or arylalkyl Ii

R

3 N-A~kyl WO 00/15240 PCT/AU99/00763 -8- In addition to the above, various neuraminic or sialic acid-containing moieties or modified neuraminic or sialic acid-containing moieties may be bonded or linked to the dendrimers in accordance with this invention. These moieties include the various N- and 0substituted derivatives of neuraminic acid, particularly N- and O-acyl derivatives such as Nacetyl, O-acetyl and N-glycolyl derivatives, as well as moieties in which the neuraminic acid group is modified. Suitable modified neuramine acid groups include groups which are substituted in the 4-position with an amino, amido, cyano, azido or guanidino group, as well as unsaturated neuraminic acid groups. These moieties may be linked to the dendrimers through the 9- or 5-NAc positions.

Preferably, in the polyionic dendrimers of the general formula I, n is an integer of from 1 to 20 or more, more preferably from 1 to 10. Preferably also, the dendrimers include at least three or more terminal groups.

The optional linking group X which may be present to act as a spacer between the dendrimer and the moiety A, may consist of an alkyl chain (optionally substituted or branched), an alkoxy, polyalkoxy, alkylthio or polyalkylthio chain (optionally substituted), or an alkenyl, multiple alkenyl, alkynyl or multiple alkynyl chain (optionally substituted).

Suitable spacer chains include groups of the formula -(CH 2 )m-Z-(CH 2 wherein Z is -CH2-, -CH=CH-, or and m is an integer of from 1 to The anionic or cationic dendrimers of this invention may be prepared by standard chemical methods which are well known to persons skilled in this art. Suitable methods are described by way of the example in Examples below.

As previously described, the anionic or cationic dendrimers of the present invention have been found to inhibit microbial and parasitic agents. The term "microbial agent" as used herein is intended to refer to both bacterial and yeast or fungal agents, particularly bacterial and yeast or fungal pathogens. Thus, the term includes, but is not limited to, Grampositive and Gram-negative bacteria such as Eschericia coli, Salmonella typhimurium, and WO 00/15240 PCT/AU99/00763 -9- Streptococcus, Staphylococcus, Shigella, Pseudomonas, Clostridium, Neisseria and Pneumococcus species. In addition, this term includes yeast pathogens such as Candida and fungal pathogens such as Aspergillusfumigatus.

The term "parasitic agent" is used herein to refer in particular to parasitic pathogens, including but not limited to parasitic agents such as Plasmodium, Trypanosoma and Leischmania species, Toxoplasma gondii, Pneumocystis carinii and Criptosporidium parvum.

The term "inhibition" is used herein in its broadest sense to include either full or partial inhibition or suppression of infection of a human or non-human animal patient by a microbial or parasitic pathogen, or full or partial inhibition or suppression of the pathogenic effects of infection of such a patient by a microbial or parasitic pathogen. The term is also used to encompass both prophylactic and therapeutic treatment.

Thus, in another aspect the present invention provides a pharmaceutical or veterinary composition for prophylactic or therapeutic inhibition of a microbial or parasitic agent in a human or non-human animal patient, which comprises a dendrimer as broadly described above, in association with at least one pharmaceutically or veterinarily acceptable carrier or diluent.

The formulation of such compositions is well known to persons skilled in this field.

Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.

The use of such media and agents for pharmaceutically active substances is well known in the art, and it is described, by way of example, in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the WO 00/15240 PCT/AU99/00763 pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the human subjects to be treated; each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier and/or diluent. The specifications for the novel dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active ingredient and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active ingredient for the particular treatment.

In yet another aspect, this invention provides the use of an effective amount of a dendrimer as broadly described above in the prophylactic or therapeutic treatment of, or in the manufacture of a medicament for prophylactic or therapeutic treatment of a human or non-human animal patient by inhibition of a microbial or parasitic agent.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practised using any mode of administration that is medically acceptable, meaning any mode that produces therapeutic levels of the active component of the invention without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, inhalation, transdermal or parenteral subcutaneous, intramuscular and intravenous) routes. Formulations for oral administration include discrete units such as capsules, tablets, lozenges and the like. Other routes include intrathecal administration directly into spinal fluid, direct introduction such as by various catheter and balloon angioplasty devices well known to those of ordinary skill in the art, and intraparenchymal injection into targeted areas.

WO 00/15240 PCT/AU99/00763 -11- The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing the active component into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active component into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active component, in liposomes or as a suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active component which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in polyethylene glycol.

Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The active component may also be formulated for delivery in a system designed to administer the active component intranasally or by inhalation, for example as a finely dispersed aerosol spray containing the active component.

Other delivery systems can include sustained release delivery systems. Preferred sustained release delivery systems are those which can provide for release of the active WO 00/15240 PCT/AU99/00763 -12component of the invention in sustained release pellets or capsules. Many types of sustained release delivery systems are available. These include, but are not limited to: erosional systems in which the active component is contained within a matrix, and diffusional systems in which the active component permeates at a controlled rate through a polymer. In addition, a pump-based hardware delivery system can be used, some of which are adapted for implantation.

The active component is administered in prophylactically or therapeutically effective amounts. A prophylactically or therapeutically effective amount means that amount necessary at least partly to attain the desired effect, or to delay the onset of, inhibit the progression of, or halt altogether, the onset or progression of the particular condition being treated. Such amounts will depend, of course, on the particular condition being treated, the severity of the condition and individual patient parameters including age, physical condition, size, weight and concurrent treatment. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgement. It will be understood by those of ordinary skill in the art, however, that a lower dose or tolerable dose may be administered for medical reasons, psychological reasons or for virtually any other reasons.

Generally, daily oral doses of active component will be from about 0.01 mg/kg per day to 1000 mg/kg per day. Small doses (0.01-1 rg) may be administered initially, followed by increasing doses up to about 1000 mg/kg per day. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localised delivery route) may be employed to the extent patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds.

The active component according to the invention may also be presented for use in the form of veterinary compositions, which may be prepared, for example, by methods that are WO 00/15240 PCT/AU99/00763 -13conventional in the art. Examples of such veterinary compositions include those adapted for: oral administration, external application, for example drenches aqueous or non-aqueous solutions or suspensions); tablets or boluses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue; parenteral administration for example by subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced into the udder via the teat; topical application, e.g. as a cream, ointment or spray applied to the skin; or intravaginally, e.g. as a pessary, cream or foam.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

BRIEF DESCRIPTION OF THE DRAWINGS In the accompanying drawings: Figure 1 shows the effect of BRI 2999 on growth of P. falciparum in human red blood cells in vitro.

Figure 2 shows the effect of BRI 6741 on growth of P. falciparum in human red blood cells in vitro.

Figure 3 shows the effect of BRI 2998 on growth of P. falciparum in human red blood cells in vitro.

WO 00/15240 PCT/AU99/00763 -14- Figure 4 shows the effect of BRI 7011 on growth of P. falciparum in human red blood cells in vitro.

Figure 5 shows the effect of BRI 6181 on growth ofP. falciparum in human red blood cells in vitro.

Further features of the present invention will be apparent from the following Examples which are included by way of illustration, not limitation of the invention. In the following Examples, PAMAM dendrimers refer to polyamidoamine dendrimers based on an ammonia core as detailed in US Patents Nos. 4,507,466, 4,558,120, 4,568,737 and 4,587,329; PAMAM (EDA) dendrimers refer to polyamidoamine dendrimers based on an ethylene diamine core; and BHAlysxlysylysz dendrimers refer to polylysine unsymmetrical dendrimers based on a benzhydrylamine core and lysine branching units as described in US Patents Nos. 4,289,872 and 4,410,688. The polyamidoamine dendrimers PAMAM 1.0, PAMAM 2.0, PAMAM 3.0, PAMAM 4.0, PAMAM 5.0 or higher generation, PAMAM 4.0 (EDA), and the polylysine dendrimers BHAlyslys 2 BHAlyslys21ys 4 BHAlyslys 2 lys4lys 8 and BHAlyslys 2 lys 4 1ys 8 lys 1 6 BHAlyslys 2 lys 4 lys 8 lys 1 lys 32 BHAlyslys2lys4lysslys16 ys64, or higher generations prepared as described in US Patents Nos. 4289872, 4410688, 4507466, 4558120, 4568737 and 4578239 and International Patent Publications Nos. WO 88/01178, WO 88/01179, WO 88/01180 and WO 95/24221 referred to above.

EXAMPLE 1 Reaction of dendritic polymers with 2-acrylamido-2-methyl propane sulfonic acid to give sulfonic acid terminated dendrimers.

A PAMAM Solid sodium carbonate (0.13g; 1.Ommol) was added slowly to a stirred solution of 2-acrylamido-2-methyl propane sulfonic acid (0.41 g; 2.0mmol) in water (3ml). After WO 00/15240 PCT/AU99/00763 the evolution of gas had ceased, the pH of the solution was 8.0. A solution of PAMAM 1.0 (0.12g; 0.33mmol) in water (lml) was then added to the solution followed by the addition of four drops of a 40% aq. solution of benzyl trimethylammonium hydroxide. The solution was then heated under nitrogen at 600 for three days and then concentrated. The residue was purified by gel filtration (Sephadex G10; water) and then freeze dried to give the sulfonated PAMAM dendrimer as an off white solid (0.51 1H and 13C nmr spectra showed a mixture of dialkylated and monoalkylated PAMAM 1.0 dendrimer ca. 70:30). 13C nmr (D 2 0): 8 31.0, 31.1, 37.1, 37.7, 41.3, 48.6, 51.5, 53.1, 53.4, 55.6, 56.2, 61.2, 61.5, 178.3, 179.0, 179.8.

B PAMAM PAMAM 2.0 was reacted with 2-acrylamido-2-methyl propane sulfonic acid as described above. The crude product was purified by gel filtration (Sephadex water) and then freeze dried to give an off white solid. 1H and 13C nmr spectra showed a mixture of dialkylated and monoalkylated PAMAM 2.0 dendrimer ca.

65:35). 3 C nmr (D 2 8 31.0, 31.1, 37.1, 37.7, 41.3, 48.7, 51.5, 53.4, 55.6, 56.2, 61.2, 61.5, 178.4, 179.0, 179.1, 179.6.

When the above reaction was repeated omitting the benzyltrimethylammonium hydroxide a similar result was obtained.

C PAMAM 3.0 BRI2783 PAMAM 3.0 was reacted with 2-acrylamido-2-methyl propane sulfonic acid as above except that a slight excess of sodium carbonate was used and the benzyltrimethylammonium hydroxide was omitted. 1H and 13C nmr spectra showed a mixture of dialkylated and monoalkylated PAMAM 3.0 dendrimer ca. 50:50). 13C nmr (D 2 8 31.0, 31.1, 36.9, 37.4, 41.1,48.6, 51.5, 53.4, 55.7, 56.2, 61.1, 61.5, 178.2, 178.9, 179.0, 179.8.

WO 00/15240 PCT/AU99/00763 -16- D PAMAM 4.0 BRI2784 PAMAM 4.0 was reacted with 2-acrylamido-2-methyl propane sulfonic acid as described for PAMAM 3.0. IH and 1C nmr spectra showed a mixture of dialkylated and monoalkylated PAMAM 4.0 dendrimer ca. 35:65). 13C nmr (D 2 6 31.0, 31.1, 36.9, 37.3, 41.1, 48.5, 51.5, 53.5, 55.7, 56.2, 61.1, 61.5, 178.1, 178.9, 179.0, 179.8.

EXAMPLE 2 Preparation of sodium sulfoacetamide terminated dendrimers.

A PAMAM A solution of 4-nitrophenyl bromoacetate (0.40g; 1.5mmol) in dry DMF (Iml) was added to a stirred solution of PAMAM 1.0 (0.18g; 0.5mmol) in DMF (3ml). The resulting yellow solution was stirred for 20 hours at room temperature, when a ninhydrin test was negative. The solution was concentrated (300/ 0.lmmHg) to give a yellow oil. This oil was partitioned between water and chloroform and the aqueous layer separated and washed with chloroform (2X) and finally with ethyl acetate. The aqueous solution was concentrated (350/ 25mmHg) to give the bromoacetylated PAMAM 1.0 dendrimer as a yellow oil (0.36g;100%). 13C nmr (D 2 6 32.8, 33.3, 43.0, 43.5, 54.4, 174.5, 176.4.

A solution of sodium sulfite (0.2g; 1.6mmol) in water (lml) was added to a solution of the bromoacetylated PAMAM 1.0 dendrimer described above (0.36g; 0.5mmol) in water (5ml) and the solution left to stand at room temperature for eleven days. The yellow solution was concentrated to give a yellowish solid (0.60g). 1C nmr (D 2 6 34.4, 43.1, 43.4, 54.0, 61.7, 171.3, 177.2.

WO 00/15240 PCT/AU99/00763 -17- The above reaction sequence could be carried out without isolating the bromoacetylated dendrimer by simply adding the sodium sulfite solution to the crude aqueous extract obtained from the first reaction.

B PAMAM Method 1: A solution of 4-nitrophenyl bromoacetate (0.18g; 0.7mmol) in dry DMF (lml) was added to a stirred solution of PAMAM 2.0 (0.10g; 0.lmmol) in DMF (3ml). The resulting yellow solution was stirred for 20 hours at room temperature, when a ninhydrin test was negative. The solution was then added with swirling to water (150ml) and the mixture extracted with chloroform (3X) and ethyl acetate. A solution of sodium sulfite (0.lg; 0.8mmol) in water (1ml) was added to the crude bromoacetylated dendrimer solution and the mixture allowed to stand for three days at room temperature. The yellowish solution was then concentrated to give a yellow solid residue, which was purified by gel filtration (Sephadex LH20; water) to give the sodium sulfoacetamide terminated PAMAM 2.0 dendrimer (103mg). 13C nmr

(D

2 8 33.0, 35.7, 36.0, 37.7, 40.3, 43.0,43.2, 53.4, 53.7, 56.0, 61.6, 171.2, 174.6, 178.5.

Method 2: Solid succinimidyl acetylthioacetate (67mg; 0.33mmol) was added to a solution of PAMAM 2.0 (52mg; 0.05mmol) in dry DMF (2ml) and the resulting solution stirred at room temperature for two days. The mixture was then concentrated (300/10-3 mmHg) to give an oily residue. The residue was partitioned between water and chloroform, and the water layer separated and concentrated to give a viscous oil (117mg). 1H and 13C nmr showed the oil to be a mixture of the acylated dendrimer and N-hydroxy succinimide. Gel filtration (Sephadex G10; water) provide a pure sample of the acetylthioacetamide terminated PAMAM 2.0 dendrimer (29mg). 13C nmr (D 2 8 34.0, 34.2, 37.3, 43.0, 43.1,43.3, 53.5, 54.0, 56.3, 175.4, 177.2, 177.5.

WO 00/15240 PCT/AU99/00763 -18- A solution of the above functionalised dendrimer in 40% aqueous formic acid (7ml) was then added to an ice cold freshly prepared solution of performic acid (1.6mmol) in formic acid (2ml). The mixture was stirred for one hour at 00 and then for twenty hours at room temperature. A small amount of activated charcoal was then added to decompose any excess peracid, the mixture stirred for 30 minutes then filtered and concentrated to give a viscous oil.

The crude product was dissolved in water, the pH adjusted to 9.0 with aqueous sodium bicarbonate and the material desalted by passage through a column of Sephadex G10. A white solid (20mg; was obtained after lyophylisation which was spectroscopically essentially the same as the material obtained by method 1. 13C nmr

(D

2 6 33.0, 38.7, 42.9, 43.0, 43.1, 53.9, 54.3, 56.5, 61.6, 171.2, 176.4, 177.0.

EXAMPLE 3 Preparation of sodium sulfosuccinamic acid terminated dendrimers A PAMAM Solid maleic anhydride (0.1 g; 1.lmmol) was added to a stirred solution of PAMAM 1.0 (0.12g; 0.33mmol) in dry DMF (3ml). The mixture became a little warm and brownish as the anhydride dissolved and the resulting solution was stirred overnight at room temperature. The solution was then concentrated (300/104 mmHg) to give a viscous oil. 1H and 13C nmr (D 2 0) showed complete conversion of the PAMAM to the trisamide together with some maleic acid. 13 C nmr (D 2 8 33.1, 42.8, 43.1, 54.3, 135.0, 137.1, 169.1, 171.9, 173.3.

The crude trisamide was then dissolved in water (4ml) and solid sodium sulfite (0.20g; 1.6mmol) added. The resulting solution was allowed to stand at room temperature for four days and then concentrated. 1H and 13 C nmr (D20) showed a 1:1 mixture of the regioisomeric sodium sulfosuccinamic acid terminated PAMAM WO 00/15240 PCT/AU99/00763 -19dendrimers together with some sulfosuccinic acid. The crude product was purified by gel filtration (Sephadex G10; water) to afford a sample of the sodium sulfosuccinamic acid terminated PAMAM 1.0 dendrimers (107mg). 13C nmr (D 2 0): 8 33.3, 39.6, 40.0, 42.9, 43.1, 54.0, 67.9, 69.4, 173.8, 176.3, 177.6, 181.8.

B PAMAM A mixture of the regioisomeric sodium sulfosuccinamic acid terminated PAMAM dendrimers was prepared as described above. C nmr PAMAM 2.0 maleamic acid derivative (D 2 8 32.8, 33.0, 38.7, 42.9, 53.8, 54.3, 56.5, 135.2, 136.8, 169.2, 171.9, 173.5, 174.6. 1 3 C nmr PAMAM 2.0 sodium sulfosuccinamic acid derivatives

(D

2 8 37.0, 40.1, 41.1, 43.0, 43.2, 43.9, 53.0, 53.3, 55.5, 68.0, 69.4, 173.8, 177.6, 179.1, 179.5, 179.8, 182.3.

C PAMAM 4.0 BRI6038 Solid maleic anhydride (60mg; 0.6mmol) was added to a stirred solution of PAMAM (51mg; 0.0lmmol) in dry DMF (2ml). The mixture initially became cloudy but soon gave a clear solution which was stirred overnight at room temperature. The solution was then concentrated (35 /10.

4 mmHg) to give a viscous oil. 'H and 3

C

nmr (D 2 0) showed complete conversion of the PAMAM 4.0 to the polyamide together with some maleic acid. The crude polyamide was then dissolved in water (2ml) and a solution of sodium sulfite (126mg; l.0mmol) in water (2ml) added. The resulting solution was allowed to stand at room temperature for two days and then concentrated. IH and 13C nmr (D 2 0) showed a mixture of the regioisomeric sodium sulfosuccinamic acid terminated PAMAM 4.0 dendrimers together with some sulfosuccinic acid. The crude product was purified by gel filtration (Sephadex water) to afford a sample of PAMAM 4.0 terminated with 24 regioisomeric sulfosuccinamic acid groups (90mg). 1 H nmr (D 2 8 2.4-2.6; 2.7-3.1; 3.2-3.4; 3.9- 3 C nmr (D 2 8 36.2; 39.8; 40.5; 43.0; 43.2; 53.5; 55.8; 68.1; 69.5; 173.8; 177.4; 177.6; 178.7; 182.3.

WO 00/15240 PCT/AU99/00763 EXAMPLE 4 Preparation of sodium N-(2-sulfoethyl)succinamide terminated dendrimers a Preparation oftetrabutylammonium N-(2-sulfoethyl)succinamic acid Solid succinic anhydride (0.5g; 5.0mmol) was added to a stirred solution of tetrabutylammonium 2-aminoethylsulfonic acid (1.83g; 5.0mmol) in dry dichloromethane (30ml). The succinic anhydride slowly dissolved and the resulting cloudy solution was stirred overnight at room temperature. The mixture was filtered and the filtrate concentrated to give a viscous oil (2.41 13C nmr showed complete conversion to the desired monoamide together with a small amount of succinic acid.

Repeated precipitation of the product by dropwise addition of a dichloromethane solution to a large excess of diethyl ether gave tetrabutylammonium N-(2sulfoethyl)succinamic acid as a white solid (1.762g; 76% mp 125-1270C. H nmr

(CDCI

3 8 0.86 12h, 4xCH 3 1.28 8H, 4xCH 2 1.50 8H, 4xCH 2 2.33 2H, CH 2 COOH), 2.44 2H, CH 2 CONH), 2.76 2H, CH 2 NHCO), 3.12 (m, 8H, 4xCH 2 3.50 2H, CH 2 SO3"), 7.53 (br t, 1H, NH). 1C nmr (CDC13): 6 13.5 ,19.5, 23.8, 30.1, 30.9, 35.6, 50.0, 58.5, 172.0, 174.1.

b Preparation of tetrabutylammonium 4-nitrophenyl N-(2-sulfoethyl)succinamate A solution of dicyclohexylcarbodiimide (45mg; 0.22mmol) in dry dichloromethane (1ml) was added to a stirred solution of tetrabutylammonium N-(2sulfoethyl)succinamic acid (94mg; 0.20mmol) in dichloromethane (2ml), and the mixture stirred overnight at room temperature. The resulting suspension was filtered and the filtrate concentrated to give the crude active ester, which was used without further purification.

WO 00/15240 PCT/AU99/00763 -21- A Preparation of sodium N-(2-sulfoethyl)succinamide terminated PAMAM dendrimers PAMAM 4.0 BRI2786 A solution of the crude tetrabutylammonium 4-nitrophenyl N-(2sulfoethyl)succinamate (0.30mmol) in dry DMF (1ml) was added to a stirred solution of PAMAM 4.0 (51.5mg; 0.Olmmol) dissolved in 50% aqueous DMF (3ml) and the resulting-yellow solution stirred overnight at room temperature. The mixture was then concentrated (350/10 5 mmHg) and the yellow residue partitioned between water and chloroform. The water layer was separated, washed with chloroform (2X) and ethyl acetate, and then concentrated to give a yellow oil (134mg). The crude product was converted to the sodium salt by passage through a column of Amberlite IR 120(Na) to yield 85mg of material. This material was further purified by gel filtration (Sephadex LH20; water) to give the sodium N-(2-sulfoethyl)succinamide terminated PAMAM 4.0 dendrimer (45mg). 1C nmr (D 2 6 33.2, 33.6, 35.5, 39.0, 39.5, 42.8, 43.2, 53.8, 54.1, 54.4, 56.6, 176.5, 176.9, 177.2, 178.9, 179.4.

The corresponding PAMAM 1.0 and PAMAM 3.0 (BRI2785) dendrimers terminated with sodium N-(2-sulfoethyl)succinamide groups were similarly prepared.

13C nmr PAMAM 3.0 derivative (D 2 6 33.4, 35.5, 39.0, 39.5, 42.9, 43.2, 53.8, 54.1, 54.3, 56.5, 176.4, 176.9, 177.4, 178.9, 179.4.

C nmr PAMAM 1.0 derivative (D 2 6 34.9, 35.5, 39.5, 42.9, 43.1, 53.7, 54.1, 179.0, 179.1, 179.3.

WO 00/15240 PCT/AU99/00763 -22- B Preparation of sodium N-(2-sulfoethyl)succinamide terminated polylysine dendrimers BHAlyslys21ys 4 lysglysl6 BR2789 Trifluoroacetic acid (1ml) was added to a suspension ofBHAlyslys 2 lys 4 lys 8

DBL

16 (36.5mg; 5.0Ozmol) in dry dichloromethane (1ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated. The residue was dissolved in dry DMSO (2ml) and the pH adjusted to 8.5 with triethylamine. A solution of the crude tetrabutylammonium 4-nitrophenyl N-(2sulfoethyl)succinamate (ca. 0.2mmol) in DMSO (Iml) was then added dropwise and the mixture stirred overnight at room temperature. The yellow solution was then concentrated (500/105 mmHg) and the yellow residue partitioned between water and chloroform. The aqueous layer was separated, washed with chloroform (3X) and ethyl acetate, and then concentrated to give an oil (99mg). The crude product was converted to the sodium salt by passage through a column of Amberlite IR 120(Na) to yield 81mg of material. This material was further purified by gel filtration (Sephadex LH20; water) to give the sodium N-(2-sulfoethyl)succinamide terminated BHAlyslys 2 lys 4 lys 8 lysl 6 dendrimer (39mg). 13 C nmr (D 2 6 27.0, 32.3, 35.2, 35.3, 35.6, 35.7, 39.5, 43.5, 54.1, 58.5, 131.5, 132.0, 133.3, 145.1, 177.8, 178.0, 178.4, 178.8, 178.9, 179.2, 179.7, 179.8.

The corresponding BHAlyslys 2 BHAlyslys 2 lys 4 (BRI2787) and BHAlyslys21ys41ys 8 (BRI2788) terminated with sodium N-(2sulfoethyl)succinamide groups were similarly prepared.

13C nmr BHAlyslys 2 1ys41ysg derivative (D 2 8 26.9, 32.3, 35.1, 35.3, 35.6, 35.7, 39.5, 43.5, 54.1, 58.5, 131.6, 131.9, 132.2, 132.3, 133.2, 133.3, 145.0, 145.2, 177.2, 177.8, 177.9, 178.0, 178.2, 178.3, 178.6, 178.7, 178.8, 178.9, 179.2, 179.3, 179.7, 179.8.

WO 00/15240 PCT/AU99/00763 -23- 13C nmr BHAlyslys21ys 4 derivative (D 2 8 26.9, 32.3, 35.1, 35.4, 35.7, 35.8, 39.5, 43.5, 54.1, 58.5, 61.8, 131.7, 132.0, 132.2, 132.3, 133.2, 133.3, 145.0, 145.1, 177.3, 178.0, 178.3, 178.4, 178.7, 178.9, 179.0, 179.3, 179.7, 179.8.

13C nmr BHAlyslys 2 derivative (D 2 8 26.9, 27.1, 32.2, 32.3, 34.7, 34.8, 35.1, 35.3, 35.6, 35.7, 39.5, 43.4, 54.1, 58.6, 61.8, 131.7, 131.9, 132.2, 132.3, 133.3, 144.9, 145.0, 177.7, 178.4, 178.8, 179.0, 179.3, 180.0.

EXAMPLE Preparation of sodium 4-sulfophenylthiourea terminated dendrimers A PAMAM 4.0 BRI2791 Solid sodium 4-sulfophenylisothiocyanate monohydrate (500mg; 1.96mmol) was added to a solution of PAMAM 4.0 (300mg; 0.0582mmol) in water (10ml) and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the yellow solid residue purified by gel filtration (Sephadex LH20; water). The pure fractions were combined and freeze dried to give the sodium 4-sulfophenylthiourea terminated PAMAM 4.0 dendrimer as a fluffy white solid (370mg). 1H nmr (D 2 0) 2.28; 2.52; 2.69; 3.15; 3.27; 3.60; 7.32 (d, J=9Hz); 7.72 J=9Hz). 13C nmr (D 2 8 36.9; 41.1; 43.1; 48.3; 53.6; 55.8; 129.0; 131.1; 144.4; 178.5; 179.1; 184.4.

The corresponding PAMAM 1.0, PAMAM 2.0 (BRI2790), PAMAM 3.0, and PAMAM 5.0 (BRI2991) dendrimers terminated with 3, 6, 12, and 48 sodium 4sulfophenylthiourea groups respectively were similarly prepared.

B PAMAM 4.0 (EDA) BRI6045 Solid sodium 4-sulfophenylisothiocyanate monohydrate (130mg; 0.5mmol) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.0lmmol) in water (4ml) and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The WO 00/15240 PCT/AU99/00763 24 solution was concentrated and the solid residue purified by gel filtration (Sephadex water). The pure fractions were combined and freeze dried to give PAMAM terminated with 32 sodium 4-sulfophenylthiourea groups as a fluffy white solid (136mg). 1H nmr (D 2 0) 6 2.30; 2.50; 2.70; 3.18; 3.62; 7.35 J=9Hz); 7.72 (d, 13 J=9Hz). 1C nmr (D 2 6 36.8; 41.0; 43.1; 48.4; 53.6; 55.7; 128.9; 131.0; 144.3; 178.5; 179.0; 184.5.

C BHAlyslys 2 lys 4 lys 8 lysI 6 BRI2792 Trifluoroacetic acid (4ml) was added to a suspension of BHAlyslys 2 lys 4 lysgDBL 16 (0.73g; 0.1mmol) in dry dichloromethane (4ml) under nitrogen. A vigorous evolution of gas was observed for a short time and the resulting solution was stirred at room temperature for two hours and then concentrated. The residual syrup was dissolved in water (5ml), the solution passed through a column of Amberlite IRA-401 (OH) and the filtrate concentrated to give BHAlyslys 2 lys 4 lysslys 16 as a viscous oil (0.49g).

The oil was redissolved in water (5ml) and N,N-dimethyl-N-allylamine buffer (pH 3ml) added. Solid sodium 4-sulfophenylisothiocyanate monohydrate (1.30g; 5.1mmol) was then added and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the brownish solid residue purified by gel filtration (Sephadex LH20; water). The pure fractions were combined, passed through a column of Amberlite IR 120(Na) and freeze dried to give the sodium 4-sulfophenylthiourea terminated BHAlyslys 2 lys 4 lysglys 16 dendrimer as a fluffy white solid (374mg). 1H nmr (D 2 6 1.40; 1.72; 3.08; 3.42; 4.24; 4.60; 7.30; 7.40 J=9Hz); 7.78 J=9Hz). 13C nmr (D 2 0) 27.3; 32.5; 35.9; 43.7; 48.9; 58.6; 63.3; 128.8; 131.0; 143.7; 144.7; 145.1; 177.7; 178.1; 183.8; 185.2.

The corresponding BHAlyslys 2 lys 4 lys 8 BHAlyslys 2 lys 4 lys 8 lys 1 6 1ys 32 (BRI2992), and BHAlyslys 2 lys 4 lys 8 lys 1 61ys 32 1ys 64 (BRI2993) dendrimers terminated with 16, 64, and 128 sodium 4-sulfophenylthiourea groups respectively were similarly prepared.

WO 00/15240 PCT/AU99/00763 EXAMPLE 6 Preparation of sodium 3,6-disulfonapthylthiourea terminated dendrimers A PAMAM 4.0 BRI2923 Solid sodium 3,6-disulfonapthylisothiocyanate (160mg; 0.41mmol) was added to a solution of PAMAM 4.0 (51 mg; 0.0 mmol) in water (3ml) and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the brown solid residue purified by gel filtration (Sephadex water). The pure fractions were combined and concentrated to give the sodium 3,6disulfonapthylthiourea terminated PAMAM 4.0 dendrimer as a brownish solid (73mg). 1H nmr (D 2 6 2.30; 2.60; 2.74; 3.20; 3.57; 7.75; 7.86; 8.28. 13C nmr

(D

2 0) 35.0; 39.9; 43.1; 48.1; 53.8; 56.1; 128.4; 128.6; 129.3; 131.0; 131.3; 136.0; 136.8; 138.2; 145.5; 146.0; 177.2; 177.8; 185.5.

The corresponding PAMAM 2.0 dendrimer terminated with sodium 3,6disulfonapthylthiourea groups was similarly prepared.

B PAMAM 4.0 (EDA) BRI6046 Solid sodium 3,6-disulfonapthylisothiocyanate (220mg; 0.57mmol) was added to a solution of PAMAM 4.0 (EDA) (74mg; 0.01mmol) in water (4ml) and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the brownish solid residue purified by gel filtration (Sephadex water). The pure fractions were combined and concentrated to give PAMAM 4.0 terminated with 32 sodium 3,6-disulfonapthylthiourea groups as a tan solid (148mg). 1H nmr (D 2 6 2.30; 2.80; 3.20; 3.54; 7.74; 7.85; 8.25. 13C nmr (D 2 0): 6 36.0; 40.8; 43.1; 48.3; 53.6; 55.9; 128.5; 129.4; 131.0; 131.3; 136.0; 136.8; 138.3; 145.5; 146.0; 178.2; 185.6.

WO 00/15240 PCT/AU99/00763 -26- C BHAlyslys 2 lys 4 1ysslys 1 6 BRI2999 Trifluoroacetic acid (2ml) was added to a suspension of BHAlyslys 2 lys 4 lyssDBL 16 (73mg; 0.0lmmol) in dry dichloromethane (2ml) under nitrogen. A vigorous evolution of gas was observed for a short time and the resulting solution was stirred at room temperature for two hours and then concentrated. The residual syrup was dissolved in water (5ml), the solution passed through a column of Amberlite IRA- 401 (OH) and the filtrate concentrated to give BHAlyslys 2 lys 4 1yslys 16 as a viscous oil. The oil was redissolved in water (5ml) and N,N-dimethyl-N-allylamine buffer (pH 9.5; 3ml) added. Solid sodium 3,6-disulfonapthylisothiocyanate (234mg; 0.60mmol) was then added and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the brownish solid residue purified by gel filtration (Sephadex LH20; water). The pure fractions were combined, passed through a column of Amberlite IR 120(Na) and freeze dried to give BHAlyslys 2 lys 4 lys 8 lysl 6 terminated with 32 sodium 3,6-disulfonapthylthiourea groups as a fluffy off-white solid (119mg). 1H nmr (D 2 8 1.0-2.0; 3.18; 3.43; 4.31; 7.22; 7.80; 7.89; 8.25. 13C nmr (D 2 0) 8 27.2; 32.4; 35.3; 43.7; 49.0; 58.5; 63.6; 128.4; 129.1; 131.4; 136.1; 136.6; 138.6; 139.0; 145.1; 145.6; 178.4; 184.8; 186.7.

EXAMPLE 7 Preparation of sodium 4-sulfonapthylthiourea terminated dendrimers PAMAM 4.0 BRI2997 Solid sodium 4-sulfonapthylisothiocyanate (180mg; 0.5mmol) was added to a solution of PAMAM 4.0 (51mg; 0.0lmmol) in water (5ml) and the mixture heated under nitrogen at 530 for two hours and then cooled. The water was distilled under reduced pressure from the resulting suspension and the off white solid residue purified by gel filtration (Sephadex water). The pure fractions were combined and freeze dried to give the sodium 4sulfonapthylthiourea terminated PAMAM 4.0 dendrimer as a fluffy white solid (60mg). 1H WO 00/15240 PCT/AU99/00763 27 nmr (D 2 0) 6 2.20; 2.60; 3.14; 3.48; 7.23; 7.47; 7.56; 7.77; 7.93 J=6Hz); 8.56 (d, J=6Hz).13C nmr (D 2 8 35.8; 40.5; 43.1; 48.4; 53.6; 55.9; 127.6; 128.6; 130.3; 131.9; 132.5; 133.5; 134.7; 140.5; 142.7; 177.8; 178.0; 185.4.

EXAMPLE 8 Preparation of sodium 3,5-disulfophenylthiourea terminated dendrimers PAMAM 4.0 BRI6039 Solid sodium 3,5-disulfophenylisothiocyanate (110mg; 0.32mmol) was added to a solution of PAMAM 4.0 (63mg; 0.012mmol) in water (3ml) and the resulting solution heated under nitrogen at 530 for two hours and then cooled. The solution was concentrated and the brownish solid residue purified by gel filtration (Sephadex G25; water). The pure fractions were combined and concentrated to give PAMAM 4.0 terminated with 24 sodium disulfophenylthiourea groups as an off-white solid (110mg). 1H nmr (D 2 8 2.53; 3.08; 3.36; 3.66; 7.90; 7.95. 13C nmr (D 2 0) 34.8; 41.0; 43.1; 48.0; 53.7; 56.2; 124.1; 128.6; 143.5; 148.8; 177.6; 185.0.

EXAMPLE 9 Preparation of sodium 3, 6, 8-trisulfonaphthylthiourea terminated dendrimers PAMAM 4.0 BR12998 Solid sodium 3, 6, 8-trisulfonaphthylisothiocyanate (250mg; 0.5mmol) was added to a solution of PAMAM 4.0 (51mg; 0.0lmmol) and N,N-dimethyl-N-allylamine buffer (pH lml) in water (2ml) and the mixture heated under nitrogen at 530 for two hours and then cooled. The mixture was concentrated under reduced pressure to give an orange solid. The residual solid was dissolved in water (2ml) and passed through a short column of Amberlite IR-120(Na). The filtrate was then concentrated and the residue purified by gel filtration (Sephadex LH20; water). The pure fractions were combined and freeze dried to give the WO 00/15240 PCT/AU99/00763 -28sodium 3, 6, 8-trisulfonaphthylthiourea terminated PAMAM 4.0 dendrimer as an off-white solid (102mg). H nmr (D 2 0) 8 2.65; 3.02; 3.30; 3.66; 8.05; 8.42; 8.59; 8.67. 13C nmr

(D

2 8 33.2; 38.7; 43.2; 43.7; 47.8; 54.0; 54.3; 56.7; 131.0; 131.3; 131.9; 135.9; 138.0; 139.6; 143.8; 144.1; 145.6; 176.2; 176.5; 186.0.

The corresponding sodium 3,6,8-trisulfonaphthylthiourea terminated dendrimer BHAlys.lyyslys41yslys 6 BRI 7011 was prepared similarly.

EXAMPLE Preparation of sodium 4-(sulfomethyl)benzamide terminated dendrimers PAMAM 4.0 BRI6040 Solid 4-nitrophenyl 4-(chloromethyl)benzoate (200mg; 0.68mmol) was added to a stirred solution of PAMAM 4.0 (70mg; 0.014mmol) in dry DMSO (4ml) and the resulting yellow solution stirred at room temperature for two hours. The solution was then concentrated (10 4 mmHg; 400) and the residue extracted with a mixture of water and dichloromethane The remaining solid material was dissolved in DMSO (5ml) and a solution of sodium sulfite (130mg; Immol) in water (3ml) added. The slightly cloudy mixture that resulted was left to stand for four days, after which time the addition of more water (2ml) resulted in the formation of a clear homogeneous yellow solution. The solution was then concentrated, first at 25mmHg and 400 then at 10-4mmHg and 500 to give the crude product. The crude product was purified by gel filtration (Sephadex G25; water) to give PAMAM terminated with 24 sodium 4-(sulfomethyl)benzamide groups (24mg). 1H nmr (D20): 8 2.25; 2.66; 3.08; 3.20; 3.33; 3.38; 4.01; 7.40 (br 7.62 (br 13C nmr (D 2 8 36.7; 40.9; 43.0; 43.6; 53.5; 55.5; 61.0; 131.6; 135.0; 137.2; 140.4; 174.5; 178.6; 179.2.

WO 00/15240 PCT/AU99/00763 -29- EXAMPLE 11 Preparation of 4-sulfobenzamide terminated dendrimers PAMAM 4.0 (EDA) BRI6116 Solid potassium N-hydroxysuccinimidyl 4-sulfobenzoate (100mg; 0.3mmol) was added to a solution of PAMAM 4.0 (EDA) (35mg; 0.005mmol) in 0.1M pH 8.5 borate buffer (5ml) and the solution stirred at room temperature for two hours. The resulting milky solution at this stage had a pH of 4.5. 1M Sodium carbonate solution (Iml) was then added to give a clear solution which was concentrated to give the crude product as a white solid. The crude product was purified by gel filtration (Sephadex G25; water) to give PAMAM 4.0 (EDA) terminated with 32 sodium 4-sulfobenzamide groups (47mg). 1H nmr (D 2 2.25; 2.42; 2.63; 3.05; 3.18; 3.31; 3.38; 7.72 J=8Hz); 7.78 J=8Hz). 13C nmr (D 2 6 36.0; 40.4; 43.0; 43.7; 53.7; 55.8; 130.2; 132.2; 140.4; 150.1; 173.6; 178.0; 178.5.

EXAMPLE 12 Preparation of Sodium N-(4-sulfophenyl)propanamide terminated dendrimers PAMAM 4.0 (EDA) BRI6117 Solid sodium N-(4-sulfophenyl)acrylamide (250mg; Immol) and solid sodium carbonate (106mg; Immol) were added successively to a stirred solution of PAMAM 4.0 (EDA) (78mg; 0.01 lmmol) in water (4ml). The resulting solution was stirred under nitrogen for four days and then freeze dried to give a fluffy white solid. The crude product was purified by gel filtration (Sephadex LH20; water to give PAMAM 4.0 (EDA) terminated with 64 1 sodium N-(4-sulfophenyl)propanamide groups (206mg). 13C nmr showed a faint trace of what was taken to be mono alkylated terminal amino groups. H nmr (D 2 0) 6 2.10; 2.48; 2.58; 2.79; 3.20; 7.42 J=7Hz); 7.65 J=7Hz). 13C nmr (D 2 6 36.5; 37.9; 41.1; 53.4; 55.6; 124.8; 130.9; 143.0; 144.2; 177.4; 178.5.

WO 00/15240 PCT/AU99/00763 EXAMPLE 13 Preparation of Sodium 4-sulfophenylurea terminated dendrimers PAMAM 4.0 (EDA) BRI6115 A solution of sodium sulfanilic acid (195mg; Immol) in dry DMSO (3ml) was added dropwise to a solution ofN,N'- disuccinimidyl carbonate (530mg; 2mmol) in dry DMSO (4ml) and the resulting brownish solution stirred at room temperature for 20 hours. A solution of PAMAM 4.0 (EDA) (75mg; 0.01 Immol) in dry DMSO (iml) added and the solution stirred for a further 18 hours. The solution was then concentrated under high vacuum (10 5mmHg; 35 to give a yellowish semi-solid. The crude product was dissolved in DMSO (4ml) and the solution added to 200ml of well stirred ethyl acetate. The precipitated white solid was collected by filtration and washed with ethyl acetate (2X) and ether then dried to give a white powder (275mg). This material was further purified by gel filtration (Sephadex LH20; water) to give PAMAM 4.0 (EDA) terminated with 32 sodium 4-sulfophenylurea groups (106mg). 1H nmr (D 2 0) 6 2.31; 2.55; 2.75; 3.19; 7.32 J=9Hz); 7.63 J=9Hz). 13C nmr (D 2 8 36.3; 40.7; 43.3; 43.8; 53.7; 55.7; 123.3; 130.9; 140.9; 146.0; 161.4; 178.2; 178.6.

EXAMPLE 14 Preparation of N,N,N-trimethylglycinamide chloride terminated dendrimers BHAlyslys 2 lys 4 1yslys 16 BRI2922 Trifluoroacetic acid (4ml) was added to a suspension of BHAlyslys 2 lys 4 lysgDBL 16 (220mg; in dry dichloromethane (2ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated. The residue was dissolved in dry DMSO (5ml) and the pH adjusted to 8.5 with triethylamine. Solid 4-nitrophenyl N,N,Ntrimethylglycinate chloride (0.50g; 1.8mmol)was then added and the mixture stirred overnight at room temperature. The cloudy solution was then concentrated (500/10-5 mmHg) WO 00/15240 PCT/AU99/00763 -31and the residue partitioned between water and dichloromethane. The aqueous layer was separated, washed with dichloromethane (3X) and ethyl acetate, and then concentrated to give an oil (1.128g). The crude product was purified by gel filtration (Sephadex water) to give the N,N,N-trimethylglycinamide terminated BHAlyslys 2 lys 4 lys 8 lys 16 dendrimer (116mg). 13 C nmr (D 2 8 25.5, 30.5, 30.8, 33.4, 42.1, 56.5, 57.1, 67.5, 68.1, 166.7, 167.0, 167.1, 176.0, 176.2.

EXAMPLE Preparation of 4-Trimethylammoniumbenzamide terminated dendrimers PAMAM 4.0 BRI6043 1,1'-Carbonyldiimidazole (85mg; 0.52mmol) was added to a solution of 4trimethylammoniumbenzoic acid iodide (154mg; 0.5mmol) in dry DMF (4ml) and the mixture stirred at room temperature under argon for two hours. During this time a white solid separated from the solution. A solution of PAMAM 4.0 (58mg; 0.01 immol) in dry DMF (2ml) was then added and the mixture stirred overnight at room temperature. After this time most of the precipitate had dissolved and a ninhydrin test of the solution was negative.

The mixture was concentrated (10 4 mmHg; 30 0) to give a white solid residue. The crude product was purified by gel filtration (Sephadex LH20; 10% AcOH) to give PAMAM terminated with 24 4-trimethylammoniumbenzamide groups as the acetic acid salt (89mg).

H nmr (D 2 6 1.96; 2.65-2.85; 3.25-3.55; 3.64; 7.92. 13C nmr (D 2 0) 8 25.8; 33.1; 33.5; 38.7; 43.1; 43.5; 53.5; 54.1; 56.4; 61.2; 124.8; 133.6; 139.9; 153.2; 173.2; 176.3; 176.8; 182.6.

The corresponding PAMAM 2.0 dendrimer terminated with 6 4-trimethylammonium benzamide groups was similarly prepared.

WO 00/15240 PCT/AU99/00763 -32- EXAMPLE 16 Preparation of 4-(Trimethylammoniummethyl)benzamide terminated dendrimers PAMAM 4.0 BRI6044 Solid 4-nitrophenyl 4-(chloromethyl)benzoate (150mg; 0.5mmol) was added to a stirred solution of PAMAM 4.0 (52mg; 0.Olmmol) in dry DMSO (3ml). The resulting yellow solution was stirred at room temperature for 20 hours, when a ninhydrin test was negative (pH ca.8.5). The solution was then concentrated 40 and the residue shaken with a mixture of water and dichloromethane The insoluble gel-like material was collected by filtration, washed with water (2X) and dichloromethane and then air dried. The crude 4-(chloromethyl)benzamide terminated dendrimer was dissolved in 25% aq. trimethylamine and the yellow solution left to stand overnight. The solution was then concentrated, the residue dissolved in water (5ml) and the solution passed through a column of Amberlite IRA-401 The colourless filtrate was concentrated to give a viscous oil which was purified by gel filtration (Sephadex G10; 10% AcOH) to give PAMAM 4.0 terminated with 24 4-(trimethylammoniummethyl)benzamide groups (90mg). 1H nmr (D 2 6 1.88; 2.65-2.80; 2.98; 3.10-3.60; 7.52 (br d, J=9Hz); 7.72 (br d, J=9Hz). 1C nmr (D 2 6 26.6; 33.4; 38.8; 43.2; 43.5; 53.6; 53.6; 54.1; 56.8; 62.8; 73.0; 132.1; 135.3; 137.5; 140.0; 176.4; 176.9; 183.6.

WO 00/15240 PCT/AU99/00763 -33- EXAMPLE 17 Preparation of N-(2-Acetoxyethyl)-N,N-(dimethylammonium)methylcarboxamide terminated dendrimers PAMAM Solid 1,1'-carbonyldiimidazole (85mg; 0.52mmol) was added to a solution of N-(2acetoxyethyl)-N-(carboxymethyl)-N,N-dimethylammonium bromide (135mg; in dry DMF (3ml) and the resulting solution stirred under nitrogen for two hours. A solution of PAMAM 4.0 (60mg; 0.012mmol) in DMF (2ml) was then added, which caused the immediate formation of a flocculant precipitate which slowly redissolved. The mixture was stirred for two days and then concentrated 4mmHg; 40 to give a viscous oil. The crude product was purified by gel filtration (Sephadex G10; 10% AcOH) to give PAMAM 4.0 terminated with 24 N-(2- Acetoxyethyl)-N,N-(dimethylammonium)methylcarboxamide groups (64mg). 1H nmr (D 2 0) 6 1.93; 2.05; 2.70; 3.10-3.60; 3.28; 3.93 4.14; 4.48 13C nmr

(D

2 0) 24.6; 26.2; 33.2; 38.7; 42.8; 42.9; 53.9; 57.4; 62.6; 67.3; 67.5; 168.9; 176.4; 176.8; 177.3; 183.2.

EXAMPLE 18 Preparation of Guanidino terminated dendrimers PAMAM 4.0 BRI6042 A solution of PAMAM 4.0 (63mg; 0.012mmol) and methylthiopseudourea sulfate (170mg; 0.61mmol) in water (5ml) (pH 10.5) was heated under nitrogen at 800 for two hours. The solution was then concentrated and the residue purified by gel filtration (Sephadex G10; 10% AcOH) to give PAMAM 4.0 terminated with 24 guanidino groups as the acetate salt (107mg). 1H nmr (D 2 6 2.00; 2.80 (br 3.09 WO 00/15240 PCT/AU99/00763 -34- (br 3.32; 3.45 (br 3.60 (br 13C nmr (D 2 0) 6 25.2; 33.2; 33.4; 38.7; 41.2; 42.6; 43.4; 44.7; 53.5; 54.0; 56.3; 176.5; 176.7; 176.9; 181.6.

The corresponding PAMAM 2.0 dendrimer terminated with 6 guanidino groups was similarly prepared.

EXAMPLE 19 Preparation of 4-([1,4,8,11-tetraazacyclotetradecane]methyl)benzamide terminated dendrimers PAMAM 4.0 BRI6041 A solution of 1-(4-carboxyphenyl)methyl- 1,4,8,11-tetraazacyclotetradecane tetra hydrochloride (120mg; 0.25mmol), N-hydroxysuccinimide (60mg; 0.52mmol) and 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (250mg; 1.3mmol) in pH 7 phosphate buffer (10ml) was allowed to stand a room temperature for one hour and then a solution of PAMAM 4.0 (32mg; 0.006mmol) in pH 7 phosphate buffer (10ml) added. The mixture was allowed to stand for two days and then concentrated. The residue was purified by gel filtration (Sephadex LH20; 10% AcOH) to give PAMAM 4.0 terminated with ca. 12 4-([1,4,8,11 -tetraazacyclotetradecane]methyl)-benzamide groups as determined by H and C nmr (80mg). The product was then dissolved in water and passed through a column of Amberlite IRA-401 (Cl) resin and then concentrated. The residue was dissolved in water (1ml), concentrated HC1 (lml) added, and the solution diluted with ethanol (30ml) to precipitate a white solid. The solid was collected by filtration (68mg). Once again H and 13C nmr showed ca. 50% functionalisation of the terminal amino groups. H nmr (D 2 6 2.17; 2.36; 2.50; 2.78; 2.85; 3.25; 3.40; 3.50; 3.60; 3.62; 4.49; 7.63 (br 7.78 (br 13C nmr (D 2 6 22.7; 23.1; 33.2; 38.8; 39.9; 40.2; 40.3; 41.0; 41.2; 42.0; 42.9; 43.2; 43.6; 45.5; 46.1; 49.1; 52.2; 53.9; 54.3; 56.6; 62.7; 132.5; 135.7; 137.1; 139.7; 174.3; 176.2; 176.3; 176.7; 177.0; 178.2; 178.5.

WO 00/15240 PCT/AU99/00763 EXAMPLE Preparation of 4-Carboxy-3-hydroxybenzylamine terminated dendrimers PAMAM 4.0 (EDA) BRI6119 Sodium cyanoborohydride (32mg; 0.5mmol) was added to a mixture of PAMAM 4.0 (EDA) (69mg; 0.0lmmol), 4-formyl-2-hydroxybenzoic acid (83mg; 0.5mmol), and sodium hydrogen carbonate (42mg; 0.Smmol) in water (4ml). The inhomogeneous orange mixture was stirred for four hours at room temperature, during which time it became homogeneous.

The orange solution was then concentrated and the residue purified by gel filtration (Sephadex LH20; water) to give PAMAM 4.0 (EDA) terminated with ca. 32 4-carboxy-3hydroxybenzylamine groups (91mg). 1H and 13C nmr (D 2 0) shows mostly mono alkylation but with some signs of dialkylation of the terminal amino groups, both spectra show broad peaks. 13C nmr (D 2 0) :6 37.0; 41.1; 50.9; 53.4; 55.5; 55.8; 61.5; 120.9; 122.2; 122.4; 132.3; 132.7; 135.0; 135.8; 163.5; 163.7; 169.0; 178.6; 179.3. 1H nmr (D 2 0) 2.20; 2.35; 2.60; 3.15; 3.30; 3.55; 4.25; 6.68; 7.12; 7.55.

EXAMPLE 21 Preparation of 4-Carboxyphenylamide terminated dendrimers PAMAM 4.0 (EDA) Solid 4-carboxyphenylisothiocyanate (86mg; 0.48mmol) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.0lmmol) in water (20ml). The pH of the resulting cloudy solution was adjusted to 9 with saturated NaHC0 3 solution and left to stir at room temperature for 24 hours. The reaction mixture was then filtered and the filtrate concentrated to give a white solid residue, which was purified by gel filtration (Sephadex LH20; water) and then freeze dried to give the product as a white fluffy solid (68mg).

WO 00/15240 PCT/AU99/00763 -36- EXAMPLE 22 Preparation of 3,5-Dicarboxyphenylamide terminated dendrimers PAMAM 4.0 (EDA) Solid 3,5-dicarboxyphenylisothiocyanate (112mg; 0.5mmol) was added to a solution of PAMAM 4.0 (EDA) (70mg; 0.0lmmol) in water (5ml). The pH of the resulting cloudy solution was adjusted to 10 with 1M Na 2

CO

3 solution and heated under nitrogen at 530 for 2 hours. The reaction mixture was then filtered and the filtrate concentrated to give a brownish solid residue, which was purified by gel filtration (Sephadex LH20; water) and then freeze dried to give the product as a pale brown solid (112mg).

EXAMPLE 23 Preparation of Sodium 4-Phosphonooxyphenylthiourea terminated dendrimers PAMAM 4.0 (EDA) Solid sodium 4-phosphonooxyphenylisothiocyanate (251mg) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.0 lmmol) in water (20ml). The resulting solution (pH 9) was stirted for 24 hours at room temperature under nitrogen. The reaction mixture was then concentrated to give a white solid residue, which was purified by gel filtration (Sephadex water) and then freeze dried to give the product as a fluffy white solid (86mg).

EXAMPLE 24 Preparation of Sodium 4-(Phosphonomethyl)phenylthiourea terminated dendrimers PAMAM 4.0 (EDA) Solid sodium 4-(phosphonomethyl)phenylisothiocyanate (97mg) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.0lmmol) in water (30ml). The resulting solution was stirred WO 00/15240 PCT/AU99/00763 -37for 3 days at room temperature under nitrogen, maintaining the pH at 8 with periodic addition of saturated NaHCO 3 solution. The reaction mixture was then concentrated to give a white solid residue, which was purified by gel filtration (Sephadex LH20; water) and then freeze dried to give the product as a fluffy white solid (102mg).

EXAMPLE Preparation of Sodium Ethyl 4-(Phosphonomethyl)phenylthiourea terminated dendrimers PAMAM 4.0 (EDA) Solid sodium ethyl 4-(phosphonomethyl)phenylisothiocyanate (109mg) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.01mmol) in DMIF (30ml). The resulting solution was stirred for 17 hours at room temperature under nitrogen, maintaining the pH at 8 with periodic addition of saturated NaHCO 3 solution. The reaction mixture was then concentrated to give a white solid residue, which was purified by gel filtration (Sephadex water) and then freeze dried to give the product as a fluffy white solid EXAMPLE 26 Preparation of Cn-alkyl linked 2-thiosialoside terminated dendrimers Methyl [(8-octanoic acid N-hydroxysuccinimide ester) 5-acetamido-4,7,8,9-tetra-O-acetyl- 3,5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosid]onate was prepared by the following procedure.

To a solution of methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-S-acetyl-3,5-dideoxy- 2-thio-D-glycero-a-D-galacto-2-nonulopyranosonate (Hasegawa et al, 1986) (100mg.) in dry dimethylformamide (lml) was added 8-bromooctanoic acid (41mg.) and diethylamine (280mg.) and the solution stirred at 200 C for 17 hours.

WO 00/15240 WO 0015240PCT/AU99100763 -38- Solvent was removed under vacuum and the residue partitioned between ethyl acetate and ice cold 5 hydrochloric acid. The organic layer was washed with water, dried over sodium sulphate, and evaporated to give a residue (l3Omg.).This was dissolved in ethyl acetate (5m1.) and N-hydroxysuccinimide (26mg.) and dicyclohexylcarbodjimiide (46mg.) were added. The mixture was stirred at 20 0 C for 17 hours then the white precipitate was filtered off. The filtrate was concentrated and purified by flash chromatography on silica gel eluting with ethyl acetate.

Fractions containing product were combined and evaporated to give a white foam 97mg. 71% Similarly were prepared: Methyl 1-undecanoic acid N-hydroxysuccinimide ester) 5-acetamido-4,7,8,9tetra-O-acetyl-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosidlonate.

Methyl [(acetic acid N-hydroxysuccinixnide ester) 5-acetamiido-4,7 ,8,9-tetra-Oacetyl-3 ,5-dideoxy-2-thio-D-glycero-cc-D-galacto-2-nonulopyranosid]onate.

Methyl [(4-butanoic acid N-hydroxysuccinimide ester) 5-acetamido-4 ,7,8 ,9-tetra-O-acetyl- 3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosidlonate.

Methyl [(4-methylbenzoic acid N-hydroxysuccinide ester) 5-acetamido-4,7,8,9-tetra-Oacetyl-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosid]onate.

A PAMAM [EDA] 4.0 [(8-octanamido)- 5-acetamido-3,5-dideoxy-2-thio-D-glyceroa-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6112 To a solution of the PAMAM [EDA] 4.0 (50mg.) in dry dimethyl sulphoxide(4m1A.) under an inert atmosphere was added methyl [(8-octanoic acid Nhydroxysuccinimide ester) 5-acetamido-4 ,7 ,8 ,9-tetra-O-acetyl-3 ,5-dideoxy-2-thio- WO 00/15240 WO 00/ 5240PCT/AU99/00763 -39- D-glycero-a-D-galacto-2-nonulopyranosid]onate(300mg.) and the solution stirred for 60 hours at 20'C. The solvent was removed under vacuum and the residue was dissolved in methanol (2m1f.). This solution was subjected to size exclusion chromatography on Sephadex LH20 eluting with methanol. On evaporation of solvent, the product, PAMAM [EDA] 4.0 [methyl [(8-octanamido) 4,7,8 ,9-tetra-O-acetyl-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-2nonulopyranosid]onatej 32 was obtained as a white powder. 182mg. 93 This was converted to the free sialoside by the following method: To a solution of PAMAM EDA 1 4.0 [methyl [(8-octanamido) 4,7, 8,9-tetra-O-acetyl-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-2nonulopyranosid]onate] 32 (182mg.) in dry methanol (3m1.) under argon at 20 0

C

was added a freshly prepared 0. 19M solution of sodium methoxide in methanol (7m1.) and the mixture stirred for 2.5 hours. The solvent was evaporated and the residue dissolved in water (l0ml.) and stirred for 3 hours. This solution was subjected to size exclusion chromatography on Sephadex LH20 eluting with water.

On lyophilisation, the product, PAMAM [EDA] 4.0 [(8-octanamido)- 3 ,5-dideoxy-2-thio-D-glycero-cc-D-galacto-2-nonulopyranosidoic acid] 32 was obtained as a pale lemon powder 110Omg. 77 By a similar procedure were prepared: PAMAM [EDA] 4.0 [(11 -undecanamido)-5-acetamido-3 ,5-dideoxy-2-thio-Dglycero-a-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6147 PAMAM [EDA] 4.0 (acetamido)- 5-acetamido-3,5-dideoxy-2-thio-D-glycero-z- D-galacto-2-nonulopyranosidoic acid] 32 BRI 6121 WO 00/15240 WO 00/ 5240PCT/AU99/00763 PAMAM [EDA] 4.0 [(4-methylbenzamido)- 5-acetamido-3,5-dideoxy-2-thio-Dglycero-a-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6120 B BHA lYSlYS 2 lYS 4 lYS 8

YS

16 [(8-octanamido)- 5-acetamido-3 ,5-dideoxy-2-thio-Dglycero-a-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6169 A solution of BHA lYSlYS 2 lYS 4 lYS 8 lYS 16 (t-Boc) 32 (20.3mg.) in a mixture of trifluoroacetic acid (2m1.) and dichioromethane (2m1.) was stirred at 20'C for 2 hours then solvent was remove d under vacuum. The residue was dissolved in dry dimethyl suiphoxide (imi.) and di-isopropylethylammne (25mg.) and methyl octanoic acid N-hydroxysuccinimide ester) 5-acetamido-4,7 ,8,9-tetra-O-acetyl-3 dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosidlonate (78mg.) were added. The mixture was stirred under argon at 20'C for 60 hours then solvent was removed under vacuum. The residue was dissolved in a freshly prepared 0. 1M solution of sodium methoxide in methanol 5m1.) and the mixture stirred for 3 hours under argon at 20TC. The solvent was evaporated and the residue dissolved in water (imi.) and stirred for 17 hours This solution was subjected to size exclusion chromatography on Sephadex LH20 eluting with water. After lyophilisation ,the product, BHA lyslys 2 lYS 4 lys 8 lYS 16 [(8-octananiido)- 3, 5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosidoic acid] 32 was obtained as a white powder 44mg. 86 EXAMPLE 27 Preparation of dendritic sialosides modified in the 4-position of sialic acid Methyl 4-azido-5-acetamido-7 ,8,9-tri-O-acetyl-2-S-acetyl-3 ,4,5-trideoxy-2-thio-D-glyceroa-D-galacto-2-nonulopyranosonate was prepared by the following procedure. To a solution of methyl 4-azido-5-acetamido-7 ,8 ,9-tri-O-acetyl-2-chloro-3 glycero-p-D-galacto-2-nonulopyranosonate (Sabesan, 1994) in dry dichioromethane WO 00/15240 PCT/AU99/00763 -41- (150ml.) was added finely powdered potassium thiolacetate and the suspension stirred vigorously at 20 0 C for 48 hours. The mixture was filtered and evaporated to give a light brown foam The required product was isolated by preparative reversed phase HPLC [C 18 30% acetonitrile/water] as a white foam 3.9g. 72%.

Methyl [(8-octanoic acid N-hydroxysuccinimide ester) 4-azido-5-acetamido-7,8,9-tri-Oacetyl-3,4,5-trideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosid]onate was prepared by the following procedure.

To a solution of methyl 4-azido-5-acetamido-7 8,9-tri-O-acetyl-2-S-acetyl-3,4,5-trideoxy- 2-thio-D-glycero-a-D-galacto-2-nonulopyranosonate (300mg.) in dry dimethylformamide was added 8-bromooctanoic acid (155mg.) and diethylamine (1.26ml.) and the solution stirred at 200 C for 17 hours. Solvent was removed under vacuum and the residue partitioned between ethyl acetate and ice cold 10% hydrochloric acid. The organic layer was washed with water, dried over sodium sulphate, and evaporated to give a yellow foam (385mg.).This was dissolved in ethyl acetate (20m1.) and N-hydroxysuccinimide and dicyclohexylcarbodiimide (175mg.) were added. The mixture was stirred at 20 0 C for 17 hours then the white precipitate was filtered off. The filtrate was concentrated and purified by preparative reversed phase HPLC [C, 8 30% acetonitrile/water] to give a white foam 340mg. 83%.

A PAMAM [EDA] 4.0 [(8-octanamido)- 4-azido-5-acetamido-3,4,5-trideoxy-2-thio- D-glycero-acx-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6146 To a solution of the PAMAM [EDA] 4.0 (72mg.) in dry dimethyl sulphoxide under an inert atmosphere was added methyl [(8-octanoic acid Nhydroxysuccinimide ester) 4-azido-5-acetamido-7,8,9-tri-O-acetyl-3,4,5-trideoxy-2thio-D-glycero-a-D-galacto-2-nonulopyranosid]onate (318 mg and the solution stirred for 60 hours at 20 0 C. The solvent was removed under vacuum and the residue was dissolved in methanol This solution was subjected to size WO 00/15240 WO 0015240PCT/AU99/00763 -42 exclus ion chromatography on Sephadex LH20 eluting with methanol. On evaporation of solvent, the product, PAMAM [EDA] 4.0 [methyl [(8-octanamido) 4-azido-5-acetamido-7 ,8 ,9-tri-O-acetyl-3 ,4 ,5-trideoxy-2-thio-D-glycero-a-Dgalacto-2-nonulopyranosid] onate 32 was obtained as a white foam. 225mg. 81 The free sialoside was obtained by the following method: To a solution of PAMAM [EDA] 4.0 [methyl [(8-octanamido) acetamido-7 ,8,9-tri-O-acetyl-3 ,4,5-trideoxy-2-thio-D-glycero-a-D-galacto-2nonulopyranosidlonate] 32 (215mg.) in dry methanol (Imi.) under argon at 200(2 was added a freshly prepared 1M solution of sodium methoxide in methanol (Imi.) and the mixture stirred for 3 hours. The solvent was evaporated and the residue dissolved in water (2m1.) and stirred for 17 hours. This solution was subjected to size exclusion chromatography on Sephadex LH20 eluting with water. On lyophilisation, the product, PAMAM [EDA] 4.0 [(8-octanamido)- 4-w7ido-5acetamido-3 ,4,5-trideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopy-'anosidoic acid] 32 was obtained as a fluffy white powder 160mg. B PAMAM [EDA] 4.0 [(8-octanamido)- 4-amino-5-acetamido-3,4,f -ti ideoxy-2-thio- D-glycero-a-D-galacto-2-nonulopyranosidoic acid] 32 BRI 6149 A slow steam of hydrogen sulphide gas was passed into a solutiin of PAMAM [EDA] 4.0 [(8-octanamido)- 4-azido-5-acetarnido-3 ,4,5-trideoxv,-2-thio-D-glyceroa-D-galacto-2-nonulopyranosidoic acid] 32 (25mg.) in a mixture of pyridine (40m1f.) and water (20m1.) at 20'C2 for 5 days. The solution was then tubbled with nitrogen for 2 hours to remove excess hydrogen sulphide. The solution was evaporated to dryness and the residue taken up in water (5 ml) and filtered through a 0.45pum.

membrane filter to remove sulphur. On lyophilisation, the product, PAMAM [EDA] 4.0 [(8-octanamido)- 4-anuno-5-acetamido-354 ,5-trideoxy-2-thio-D-glycero- WO 00/15240 PCT/AU99/00763 -43a-D-galacto-2-nonulopyranosidoic acid] 32 was obtained as a fluffy white powder 23mg. 96% EXAMPLE 28 Preparation of boronic acid terminated dendrimers.

4-Carboxyphenylboronic acid N-hydroxysuccinimide ester To a solution of 4-carboxyphenylboronic acid (500mg.) in dry dimethyl formamide were added N-hydroxysuccinimide (380mg.) and dicyclohexylcarbodiimide (680mg) The mixture was stirred at 200 C for 64 hours then the white precipitate was filtered off. The solvent was removed under vacuum and the residue dissolve in ethyl acetate (100ml.).

This solution was washed with water, dried over sodium sulphate and evaporated to give a white solid which was crystallised from acetonitrile/water as fine needles 730mg. 92% PAMAM [EDA] 4.0 [4-benzamidoboronic acid] 32 BRI 6160 To a solution of the PAMAM [EDA] 4.0 (69mg.) in dry dimethyl sulphoxide (5ml) under an inert atmosphere was added 4-carboxyphenylboronic acid N-hydroxysuccinimide ester (130mg.) and the solution stirred for 65 hours at 20 0 C. To the thick slurry was added 1M sodium carbonate solution (1ml.) and the clear solution stirred an additional 24 hours. The solvent was removed under vacuum and the residue was dissolved in 10% ammonia solution This solution was subjected to size exclusion chromatography on Sephadex LH20 eluting with 10% ammonia solution On evaporation of solvent, the product, PAMAM [EDA] [4-benzamidoboronic acid] 32 was obtained as a white fluffy solid. 110mg. 94%.

WO 00/15240 PCT/AU99/00763 -44- EXAMPLE 29 Preparation of Sodium 3,6-disulfonaphthylthiourea terminated dendrimers.

BHAlyslys 2 lys 4 lys6lys 1 6 lys 32 Trifluoroacetic acid (2ml) was added to a stirred suspension of BHAlyslys2lys 4 lys1lys 1 6

DBL

32 (147mg) in dry dichloromethane (2ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated.

The residue was dissolved in N,N-dimethyl-N-allylamine buffer (pH 9.5; 5ml) and then solid 3,6-disulfonaphthyl isothiocyanate (400mg) added. The pH of the mixture was then adjusted to 9.5 by the addition of 1M sodium carbonate and the solution heated at 53 °C for three hours under nitrogen. The reaction mixture was concentrated and the residue redissolved in water and the solution passed through a column of Amberlite IR 120 (Na).

The filtrate was concentrate was concentrated to give the crude product, which was purified by gel filtration (Sephadex LH20; water) to give BHAlyslys 2 lys 4 lySlys 6 lys 32 with 64 sodium 3,6-disulfonaphthylurea groups as a white fluffy solid (175mg).

EXAMPLE Preparation of Sodium 3,5-Disulfophenylthiourea terminated dendrimers.

BHAlyslys 2 lys 4 lys 8 lys 6 lys 32 Trifluoroacetic acid (3ml) was added to a stirred suspension of BHAlyslys 2 lys 4 lyslys 1 6

DBL

32 (300mg; 0.02mmol) in dry dichloromethane (3ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated. The residue was dissolved in water and the solution passed through a column of Amberlite IRA 401 (OH) and the filtrate concentrated to give a viscous oil (187mg). The oil was dissolved in a 1:1 mixture of pyridine/water (8ml) and solid sodium disulfophenyl isothiocyanate (680mg; 2mmol) added. The resulting solution was heated at 53 °C for three hours under nitrogen. The solution was then concentrated to give a white WO 00/15240 PCT/AU99/00763 solid residue. The crude product was purified by gel filtration (Sephadex LH20; water) to give BHAlyslys 2 lys 4 lys 8 lys 1 l 32 with 64 sodium 3,6-disulfophenylurea groups as a white fluffy solid.

EXAMPLE 31 Preparation of Sodium 3,5-Dicarboxyphenylthiourea terminated dendrimers.

BHAlyslys 2 lys41ylys 6 ,1ys 3 2 BRI 6741 Trifluoroacetic acid (3ml) was added to a stirred suspension of BHAlyslys 2 lys 4 lyslys 1 6

DBL

3 2 (300mg; 0.02mmol) in dry dichloromethane (3ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated. The residue was dissolved in water and the solution passed through a column ofAmberlite IRA 401 (OH) and the filtrate concentrated to give a viscous oil (186mg). The oil was dissolved in a 1:1 mixture of pyridine/water (8ml) and sodium isothiocyanate (450mg; 2mmol) added. The resulting solution was heated at 53 C for 13 hours under nitrogen. The solution was then concentrated to give a white solid residue. The crude product was purified by gel filtration (Sephadex LH20; water) to give BHAlyslys 2 lys 4 lysl1ys 1 l 32 with 64 sodium 3,6-dicarboxyphenylurea groups as a white fluffy solid.

The corresponding sodium 3,5-dicarboxyphenylthiourea terminated dendrimer PAMAM (EDA) BRI 6195 was similarly prepared.

WO 00/15240 PCT/AU99/00763 -46- EXAMPLE 32 Preparation of Sodium 4-phosphonooxyphenylthiourea terminated dendrimers.

BHAlyslys 2 lys4ys 8 lys 16 lys 3 2 BRI6181 Trifluoroacetic acid (2ml) was added to a stirred suspension of BHAlyslys 2 lys 4 ylysi6DBL 3 2 (147mg; 0.01 mmol) in dry dichloromethane (2ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated to give a viscous oil. The oil was dissolved in N,N-dimethyl-N-allylamine buffer (pH 9.5; 5ml) and solid 4-phosphonooxyphenyl isothiocyanate (250mg) added. The pH of the resulting solution was adjusted to 10 with 1M sodium carbonate and the mixture heated at 53 °C for three hours under nitrogen. The solution was then concentrated to give a white solid residue. The residue was redissolved in water and the solution passed through a column ofAmberlite IR 120 (Na) and the filtrate concentrated. The residue was then purified by gel filtration (Sephadex LH20; water) to give BHAlyslys 2 ys 4 lyselys 61yS 3 2 with 64 sodium 4-phosphonooxyphenylurea groups as a white fluffy solid (150mg).

EXAMPLE 33 Preparation of Sodium 4-phosphonophenylthiourea terminated dendrimers.

BHAlyslys 2 lys4yslysl61ys 32 Trifluoroacetic acid (2ml) was added to a stirred suspension of BHAlyslys 2 lys 4 lys 8 lys 6

DBL

32 (147mg; 0.01 mmol) in dry dichloromethane (2ml) and the resulting solution stirred at room temperature under nitrogen for two hours and then concentrated to give a viscous oil. The oil was dissolved in N,N-dimethyl-N-allylamine buffer (pH 9.5; 5ml) and solid 4-phosphonophenyl isothiocyanate (250mg) added. The pH of the resulting solution was adjusted to 9 with saturated sodium bicarbonate solution and the mixture heated at 53 C for three hours under nitrogen. The solution was then concentrated to give a white solid residue. The residue was redissolved in water and the WO 00/15240 PCT/AU99/00763 -47solution passed through a column of Amberlite IR 120 (Na) and the filtrate concentrated.

The residue was then purified by gel filtration (Sephadex LH20; water) to give BHAlyslys 2 lys 4 lysly 1 6 ys 3 2 with 64 sodium 4-phosphonophenylurea groups BRI 6196 as a white fluffy solid (152mg) after freeze drying.

EXAMPLE 34 Preparation of Sodium 4,6-diphosphononaphthylthiourea terminated dendrimers.

PAMAM A solution of sodium 4,6-diphosphononaphthyl isothiocyanate (165mg) in water (2ml) was added to a solution of PAMAM 4.0 (5 1mg; 0.Olmmol) in water (2ml). The pH of the mixture was adjusted to 9.5 with saturated sodium bicarbonate solution and the mixture vigorously stirred for one hour at room temperature and then heated at 53 °C for three hours under nitrogen. The mixture was then filtered and the filtrate concentrated to give a brown solid residue. The crude product was purified by gel filtration (Sephadex G25; water) to give PAMAM 4.0 terminated with 24 sodium 4,6-diphosphononaphthylthiourea groups as a brown solid (81mg) after freeze drying.

EXAMPLE Preparation of Fluoresceinthiourea terminated dendrimers.

PAMAM 4.0 (EDA) Solid fluorescein isothiocyanate (188mg) was added to a solution of PAMAM 4.0 (EDA) (74mg; 0.0lmmol) in water (3ml). Saturated sodium bicarbonate solution was added to adjust the pH to 9 and the resulting homogenous solution stirred overnight at room temperature and then concentrated. The orange residue was purified by gel filtration (Sephadex LH20; water) to give PAMAM 4.0 (EDA) terminated with 21 fluoresceinthiourea groups as a fluffy orange solid (193mg) after freeze drying.

WO 00/15240 PCT/AU99/00763 -48- EXAMPLE 36 Preparation of Sodium (phenyl-3-boronic acid)-thiourea terminated dendrimers.

PAMAM 4.0 (EDA) Solid (phenyl-3-boronic acid) isothiocyanate (100mg; 0.5mmol) was added to a solution of PAMAM 4.0 (EDA) (69mg; 0.0lmmol) in water (5ml). 1M sodium carbonate was added to the isothiocyanate dissolved (pH ca.10). The mixture was then heated at 53 C for two hours under nitrogen, and then filtered and the filtrate concentrated to give a brownish solid residue. The crude product was purified by gel filtration (Sephadex LH20; water) to give PAMAM 4.0 (EDA) terminated with 32 (phenyl-3-boronic acid)thiourea groups as a white fluffy solid (87mg) after freeze drying.

EXAMPLE 37 Preparation of Pyridinium dodecyl carboxamido-terminated dendrimers.

PAMAM 2.0 dendrimer. BRI-6807 PAMAM generation 2.0 core (0.0479mmol; 50mg) was evaporated from a 0.5ml solution in MeOH and then re-dissolved in 10 ml of water. 1-N- pyridinium 12-dodecanoic acid bromide (0.14g; 0.384mmol), N-hydroxybenzotriazole hydrate [HOBT] (52mg; 0.384mmol) triethylamine (53/l 0.384mmol) and 1-(3-diethylaminopropyl-3-ethyl) carbodiimide .HCI [EDC] (74mg; 0.384mmol), were added to the solution. This reaction mixture was stirred overnight at room temperature. The volume was reduced to a third under reduced pressure and the solution was chromatographed on a LH20 column using water as the eluent. Fractions containing the product were collected and pyridinium dodecylcarboxamide PAMAM 2.0 bromide isolated as a fluffy white solid by freeze drying.

'H nmr (D 2 8 1.15, 1.45, 1.9, 2.15, 2.75, 2.8, 3.15, 3.35, 3.5, 4.55, 8.05, 8.5, 8,8.

WO 00/15240 PCT/AU99/00763 -49- PAMAM 4.0 dendrimer. BRI-6809.

PAMAM generation 4.0 core (0.05mmol; 69mg) was evaporated from a 1.0ml solution in MeOH and then re-dissolved in 15 ml of water. 1-N- pyridinium 12-dodecanoic acid bromide (0.143g; 0. 4mmol), N-hydroxybenzotriazole hydrate [HOBTI (77mg; 0.4mmol); triethylamine (56pl 0. 4mmol) and 1-(3-diethylaminopropyl-3-ethyl carbodiimide .HC1 [EDC] (77mg; 0.4mmol) were added to the solution.

This reaction mixture was stirred overnight at room temperature. The volume was reduced to a third under reduced pressure and the solution was chromatographed on a LH20 column using 1% triethylamine in water as the eluent. Fractions containing the product were collected and the pyridinium dodecylcarboxamide PAMAM 4.0 bromide was isolated as fluffy white solid by freeze drying.

A small amount of the product was reacted with acetic anhydride to confirm the complete capping of the NH 2 end groups of the dendrimer core.

'H nmr (D 2 8 1.10, 1.45, 1.9, 2.1, 2.30, 2.5, 2.7, 3.2, 4.5, 8.00, 8.45, 8.80.

EXAMPLE 38 Preparation of saccharin-terminated dendrimers.

PAMAM 4.0 Dendrimer BRI-6157 To a solution of ethylenediamine core PAMAM 4.0 dendrimer core (275mg; 39.8uM) in dry dimethyl formamide (25ml) was added 6-(benzosulfimido) isothiocyanate (400mg; 1.67mM) and the mixture stirred at room temperature for 24 h. The cloudy solution was clarified by the adjustment of the pH with sodium carbonate solution to pH10-10.5. This solution was stirred for a further 24 h and volatiles removed on a rotary evaporator. The solution was chromatographed on a large Sephadex LH20 column and front fraction collected. The remaining fractions were collected and re-chromatographed on a smaller column. The combined front fractions were evaporated and freeze dried to yield the saccharin-terminated dendrimer product (450mg; 78%) as a fluffy white solid.

'H nmr (D 2 8 2.20, 2.50 3.23, 3.46, 3.63, 7.52, 7.87.

WO 00/15240 PCT/AU99/00763 The corresponding saccharin-terminated BHA.Lys.LysLys 4 .Lyss.ys s 6 .Lys 3 2 dendrimer BRI-6189 was similarly prepared.

EXAMPLE 39 In vitro anti parasitic assays The following assay was performed as an in vitro assay to test for inhibition of trypanosomes.

A Materials and Methods Medium "Balz-MEM" plus 10% heat-inactivated horse serum.

Trypanosome strains Standard drugs STIB 900 b. rhodesiense cloned from STIB 704) STIB 920 brucei cloned from STIB 348) STIB 930 gambiense cloned from STIB 754).

Melarsoprol (Arsobal, Specia, France), Pentamidine (Pentacarinat, Rhone-Poulenc), Suramin (Germanin, Bayer, Germany).

Incubation conditions 72 hours at 37 0 C and 5% CO 2 in a humid atmosphere.

Test system 96 well microtitre plate, 100 pl per well, 200-1000 trypanosomes per well (depending on the strain) and evaluation with two end point readings.

a. By microscopical determination of the MIC b. Fluorescent reading after BCECF/AM addition or counting the cells with Coulter Counter or CASY.

Evaluation WO 00/15240 PCT/AU99/00763 -51- Drug preparation Stock solution of 10 mM in 10% solvent (DMSO, ethanol etc.), highest drug concentration is 50 pM.

Detailed Test Procedure The test is based on LILIT: Low Inoculum Long Incubation Test (Brun and Lun Vet. Par. 52 (1994) 37-46).

1. Add 50pl of complete medium into wells of rows B-H, column numbers 2-10 of a 96 well plate (marked wells).

2. Add 75pl of medium containing two times the highest drug concentration to be tested in wells B-D and F-H (D 2 column number 11.

3. Prepare serial dilutions using a multipipette by transferring 25gtl from wells number 11 into wells number 10 and mix by sucking and dispensing medium a minimum of times.

4. Continue with the dilution from right to left direction until 25 pl is added from well number 5 into well number 4. After mixing the remaining 25 pl is discarded. Wells number 2 and 3 in each row serve as control wells without drug.

5. Add 50pl oftrypanosome suspension into wells B, C and F, G numbers 2-11 of the plate with a seeding density of 4 x 10 3 /ml (makes 200/well). Add 50ul of Baltz medium without trypanosomes to wells 2-11 of rows D and E as background controls for the fluorescence assay.

6. Incubate plate for 72 hours at 37 0 C, 5% CO 2 7. Observe the plate under an inverted microscope to determine microscopically the MIC (Minimal Inhibitory Concentration): lowest drug concentration at which no trypanosome with normal morphology and motility as compared to control wells can be seen or the concentration at which no trypanosome survived.

WO 00/15240 PCT/AU99/00763 -52- 8. The test can be further evaluated by fluorescence reading after the addition of BCECF/AM or by growth inhibition assessment by Coulter Counter.

B. Results The following dendrimers were tested.

BRI Number MOL Name Type of compound BRI 2923 PAMAM 4.0(NHCSNHNapth[SO 3 Na] 2 24 dendrimer BRI 2998 PAMAM 4.0(NHCSNHNapth-3,6,8-triSO 3 Na) 24 dendrimer BRI 6039 PAMAM 4.0(NHCSNH- -Ph-3,5-[SO 3 Na] 2 24 dendrimer BRI 6041 PAMAM 4.0(NHCOPhCH 2 cyclam.4HCl) 32 dendrimer BRI 6042 PAMAM 4.0(NHC=NHNH 2 .HOAc) 24 dendrimer In vitro activity of 4 compounds tested against T.b. rhodesiense (STIB 900) in a 72 hr fluorescence assay. All compounds were dissolved in distilled water at a concentration of 4 mg/ml and then diluted to the desired concentration in complete cultivation medium.

Compound MTC (pg/ml) MIC (pg/ml) ECso (pg/ml) BRI 2998 >100 3.7 7 333 4.1 6.3 MIC minimum inhibition concentration (no trypanosomes alive) MTC maximum tolerated concentration (no drug effect).

(ii) In vitro activity of 5 compounds tested against T.b.rhodesiense (STIB 900) in a 72 hr fluorescence assay. All compounds were dissolved in distilled water at a WO 00/1 5240 PCT/AU99/00763 53 concentration of 20 jig/mi and then diluted 1: 10 in complete cultivation medium (BMEM plus 10% HI horse).

Compound MTC MIC EC 50 g/mI ftM gIgmI tM ~Ig/m1 ~IM BRI 6042 666 87.7 74 9.7 120 15.8 BRI 6041 666 62.3 74 6.9 190 BRI 6039 1000 75.2 112.3 J0.9 22 1.65 BRI 2923 >1000 >70 37 2.5 170 II The following assay results were obtained in an in vitro assay to test for inhibition of Trypanosoma and Plasmodiumn species.

The following compounds were tested: BRI MOL Name Number BRI 6157 PAMAM 4.0 EDA(NHCSNH Polyamide amine core saccharin SaccbarinNa) 32 substituted dendrimer BRI 6181 BHAlYS 31 lYS 32 (NHCS NHPhOP[O] Lysine core phenyl phosphate [ONa] 2 )64 substituted dendrimer BRI 6195 PAMAM 4.0 EDA(NHCSNH-3,5 Ph Polyamide amine core phenyl

[COOH]

2 32 carboxylate substitute dendrimer The tests were conducted using the following strains: Parasite Strain Stage Standard Tb. rhodesiense P~falciparum STIB 900 NF54 trypomnastigotes Melarsoprol all Chloroquine WO 00/15240 PCT/AU99/00763 54- Results (all values as utg/ml) Compound Tb. rhodesiense Pfalciparum Cytotoxicity MIC IC-50 IC-50 MIC BRI6157 33 5 22 >100 BRI6181 >100 >100 24 >100 BRI6195 >100 >100 20 >100 EXAMPLE Determination of Antibacterial Activity.

Bacteria used in this assay were Staphylococcus aureus (ATCC 29213) Enterococcusfaecalis (ATCC29212) Escherichia coli (ATCC 25922) Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were determined by micro broth dilution (NCCLS M7A3 1993) in Cation Adjusted Mueller-Hinton Broth (pH 7) using inoculum 2-5 x 104 cfu (log phase) and incubation for 24 and 48 h at 35 0 C, aerobically. MBC is taken as titre showing 3 log reduction of inoculum.

The results are set out in the following table (all units in tg/ml).

Test Compound S. aureus E. faecalis E. coli BRI-6807 32; (128) >256 128 BRI-6809 8; 128 (128) >256 MIC= Minimum Inhibitory Concentration (MBC)= Minimum Bactericidal Concentration WO 00/15240 PCT/AU99/00763 EXAMPLE 41 Quantification of the effect of dendrimers on invasion and growth of the human malaria parasite Plasmodiumfalciparum in human red blood cells in vitro.

Methods Malaria Parasites. 3D7 is a well characterised in vitro culture-adapted line of P.

falciparum. The parasite undergoes repeating cycles of growth and replication within human red blood cells. The duration of each cycle is 48 hours beginning with young ring-stage parasites that mature through pigmented trophozoites (during the first 24 hours of the cycle) to segmented schizonts that burst to release infectious merozoites that rapidly invade fresh red cells. Newly invaded merozoites become ring forms and the cycle repeats.

Parasite culture and growth assays. P. falciparum (line 3D7) parasites were maintained in synchronous in vitro culture in freshly collected human red blood cells using wellestablished techniques. For invasion assays, red cells containing mature, pigmented trophozoites were purified by gelatin flotation then resuspended in fresh human red blood cells so that approximately one in every 200 red blood cells was parasitised (0.5 parasitaemia). Fresh culture media was then added to give a final red cell concentration of 2 x 108 red cells/ml.

Aliquots of the red cell suspension (each of 95/ul) were dispensed in duplicate into 96 well plates. 5 gl of parasite culture media containing either the test compound (BRI 2999; BRI 6741; BRI 2998; BRI 7011; BRI 6181) or PBS (control) was added to appropriate wells and the plates incubated at 37 0 C and 1% 02. Thin smears from each of the wells were made immediately (time 0) then subsequently after 24, 48 and 72 hours of culture. From each smear parasitaemia and stage of parasite maturation was quantified by microscopic examination of the smears after staining with Giemsa at pH 7.2. This allowed invasion, parasite development and subsequent re-invasion to be quantified. At each sampling time P:\OPER\JMS\58416-98.WPD- 11/9/03 -56point, the culture media (either with or without compound) in the remaining wells was completely replaced.

The test compounds were first dissolved at 20mg/ml in sterile isotonic phosphate-buffered saline (pH then further diluted to make concentrated stock solutions ranging between 1mg/ml and 200htg/ml. Stock solutions were stored at 4 0 C throughout the duration of an assay and diluted appropriately in parasite culture media when required.

Results Separate invasion/growth experiments were performed for each compound and the results are presented graphically in Figures 1 to 5. The effect of each compound was tested at final concentrations of 10, 25 and.50. ig/ml. Each of the five compounds showed a concentrationdependent inhibitory effect on parasite invasion, growth and replication, for any given concentration, the absolute level of inhibition did vary between the different compounds. At all concentrations tested (up to and including 50 ug/ml), none of the five test compounds had any obvious unfavourable effect on red blood cell morphology. In experiments in which BRI 7011 and BRI 6181 were tested (Figs. 4 the level of re-invasion of parasites in control wells at 72 hours was lower than normally observed. This was due to an apparent retardation in parasite growth sometime after 48 hours of culture such that at 72 hours, a large proportion of the schizonts had not yet burst to release invasive merozoites.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Claims (13)

1. (Amended) A method of prophylactic or therapeutic inhibition of a bacterial, yeast, fungal or parasitic agent in a human or non-human animal patient, which comprises administration to the patient of an effective amount of a dendrimer having a plurality of terminal groups wherein at least one of said terminal groups has an anionic- or cationic-containing moiety bonded or linked thereto.

2. A method according to claim 1, wherein said compound is a dendrimer which comprises a polyvalent core covalently bonded to at least two dendritic branches, and extends through at least two generations.

3. A method according to claim 2 wherein said dendrimer is a polyamidoamine dendrimer based on an ammonia core.

4. A method according to claim 2 wherein said dendrimer is a polyamidoamine dendrimer based on an ethylene diamine core.

A method according to claim 2 wherein said dendrimer is a polylysine dendrimer based on a benzhydrylamine or other suitable core.

6. A method according to claim 2 wherein said dendrimer is a poly(propyleneimine) dendrimer.

7. A method according to claim 2 wherein said compound is a polyionic dendrimer of the general formula I: AMEDFD SH' T IPEA/AIU WO 00/15240 PCT/AU99/00763 -58- A A AA A A A A wherein: I is an initiator core; Z is an interior branching unit; n is an integer which represents the number of generations of the dendrimer; and A is an anionic- or cationic- containing moiety which may be linked to interior A A A A A A A A AA A wherein: I is an initiator core; Z is an interior branching unit; n is an integer which represents the number of generations of the dendrimer; and A is an anionic- or cationic- containing moiety which may be linked to interior branching unit Z through an optional linking group X.

8. A method according to any of claims 1 to 7 wherein in said compound said anionic- or cationic-containing moiety or moieties are bonded to amine, sulfhydryl, hydroxy or other reactive terminal groups of the dendrimer by amide or thiourea linkages. WO 00/15240 PCT/AU99/00763 -59-

9. A method according to any of claims 1 to 8, wherein in said compound said anionic- or cationic-containing moieties are selected from the group consisting of sulfonic acid-containing moieties, carboxylic acid-containing moieties (including neuraminic and sialic acid-containing moieties and modified neuraminic and sialic acid-containing moieties), boronic acid-containing moieties, phosphoric and phosphonic acid-containing moieties (including esterified phosphoric and phosphonic acid-containing moieties), primary, secondary, tertiary or quaternary amino-containing moieties, pyridinium-containing moieties, guanidinium- containing moieties, amidinium-containing moieties, phenol-containing moieties, heterocycles possessing acidic or basic hydrogens, and zwitterionic-containing moieties.

A method according to any of claims 1 to 9 wherein in said compound the moiety or moieties which are bonded to amino or other reactive terminal groups of the dendrimer are selected from the following groups, in which n is zero or a positive integer: NH(CH 2 )nSO 3 (CH 2 )nSO 3 Ar(SO3)n -CH 2 CH(S0)COOH CH(S 3 )CH 2 COOH ArX(CH 2 )nSO3 X S. NH -(CH 2 )NMe3 Ar(NMe 3 Ar(CH 2 NMe)n WO 00/15240 WO 0015240PCT/AU99/00763 60 H 0 AV, SO 3 Na 0 HN(VSON 0 /k".,S,03Na 1\ COOH HA SO 3 Na HA NaO 3 S~b S03Na S HA) S0 3 Na NaO S c~S03Na 0 HA* S03Na HNk' S0 3 Na 0 S0 3 Na 0 S%Na ~OH COOH 0 AX^OAC 0 AVY A~me 3 0 t&%e 3 AM6 IH -ArXP(=O)(OR) 2 X0O, OH 2 CHF, CF 2 R=alkyl, aryl, H, Na. -ArXP(=O)(R)(NR 2 R 3 X=O, CH 2 CHF, CF 2 R'=alkyl, aryl, H, Na R 2 R 3 =alkyl, aryl 2 R=alkyl, aryl, H, Na n=1-3 -AB(OH) 2 n=1-3 -ACOOH], n=1 -3 s HN PO(OEt) 2 HN COONa S HN PO(OEt)(ONa) s HN P O(ONa) 2 S HNN PO(ONa) 2 PO(ONa) 2 S MN' NaOOC 6 COONa S HN 'N SB(ONa) 2 0 B(ONa) 2 WO 00/15240 WO 00/ 5240PCT/AU99/00763 -61- S HNII PO(ONa) 2 HN PO(Ot) (ONa) HNJL<" PO(OEt) 2 HNK HN-%H 0,PO(ONa) 2 po(OEt)(ONa) 0.POPE 2 HNyK NH -CH 2 NH 2 R Ii>-NH n r2rco N -NR 3 NH N -aO )CF 3 N H -N--NR 3 t -Nt-R-C00- -N+-R-SO3- 0 11/0, -N+-R-P \OH R 3 C\ -\,N-AkyI R= alkyl or arylalkyl; RI, R 2 R 3 (which may be same or different) alkyl or arylalkyl WO 00/15240 WO 0015240PCTIAU99/00763 62

11. A method according to any of claims 1 to 10, wherein said compound is selected from the group consisting of: 1. alkylsulfonic acid terminated dendriiners; 11. sulfoacetamide terminated dendrimers; iii. sulfosuccinamic acid terminated dendrimers; iv. N-(2-sulfoethyl). succinamide terminated dendrimers; v. 4-sulfophenylthiourea terminated dendrimers; vi. 3, 6-di-sulfonaphthylthiourea terminated dendrimers; vii. 4-sulfonaphthylthiourea terminated dendrimers; viii. 3 ,5-di-sulfophenylthiourea terminated dendrimers; ix. 3 ,6,8-tri-sulfonaphthylthiourea terminated dendrimers; x. 4-(sulfomethyl) benzainide terminated dendrimers; xi. 4-sulfobenzamide terminated dendrimers; xii. N-(4-sulfophenyl) propanamide terminated dendrimers; xiii. 4-sulfophenylurea terminated dendrimers; xiv. N,N ,N-tri-methylglycinamide terminated dendrimers; xv. 4-trimethylammonium benzamide terminated dendrimers; xvi. 4-(trimethylanimoniummethyl)benzamide terminated dendrimers; xvii. N-(2-acetoxyethyl)-N ,N-(dimethylammonium)methyl-carboxamide terminated dendrimers; xviii. guanidino terminated dendrimers; xix. 11-tetraazacyclotetradecane]methyl)benzamide terminated dendrimers; xx. 4-carboxy-3-hydroxy-benzylamine terminated dendrimers; xxi. 4-carboxyphenylamide terminated dendrimers; xxii. 3 ,5-dicarboxyphenylamide terminated dendrimers; WO 00/15240 WO 0015240PCT/AU99/00763 63 xxiii. 4-phosphonooxyphenylthiourea terminated dendrimers; xxiv. 4-(phosphonomethyl)phenylthiourea terminated dendrimers; xxv. ethyl-4-(phosphonomethyl)phenylthiourea terminated dendrimers; xxvi. (8-octanamido)-5-acetamido-3 ,5-dideoxy-2-thio-D-glycero-a-D- galacto-2-nonulopyranosidoic acid terminated dendrimers; xxvii. (1 1-undecanamido)-5-acetamido-3 ,5-dideoxy-2-thio-D-glycero-a-D- galacto-2-nonulopyranosidoic. acid terminated dendrimers; xxviii. (acetamido)-5-acetamido-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto- 2-nonulopyranosidoic acid terminated dendrimers; xxix. (4-butanamido)-5-acetamido-3 ,5-dideoxy-2-thio-D-glycero-a-D- galacto-2-nonulopyranosidoic acid terminated dendrimers; xxx. (4-methylbenzamido)-5-acetam-ido-3 ,5-dideoxy-2-thio-D-glycero-a- D-galacto-2-nonulopyranosidoic acid terminated dendrimers; xxxi. (8-octanamido)-4-azido-5-acetamido-3 ,4,5-trideoxy-2-thio-D- glycero-a-D-galacto-2-nonulopyranosidoic acid terminated dendrimers; xxxii. (8-octanamido)-4-amino-5-acetamido-3 ,4,5-trideoxy-2-thio-D- glycero-cz-D-galacto-2-nonulopyranosidoic acid terminated dendrimers; xxxiii. 4-benzamidoboromic acid terminated dendrimers; xxxiv. 3,5-dicarboxyphenylthiourea terminated dendrimers; xxxv. 4-phosphonooxyphenylthiourea terminated dendrimers; xxxvi. 4-phosphonophenylthiourea terminated dendrimers; xxxvii .4 ,6-diphospliononaphthylthiourea terminated dendrimers; xxxviii fluoresceinthiourea terminated dendrimers; xxxix. (phenyl-3-boronic acid)-thiourea terminated dendrimers; X1. pyridinium. dodecylcarboxamide terminated dendrimers; and P:\OPER\JMS\58416-98.WPD 11/9/03 -64- xll. saccharin terminated dendrimers.

12. A method according to any of claims 1 to 11, wherein said treatment comprises inhibition of bacterial, yeast or fungal pathogens, or parasitic pathogens..

13. Use of an anionic or cationic dendrimer as defined in any of claims 1 to 11, in, or in the manufacture of a medicament for, prophylactic or therapeutic inhibition of a microbial or parasitic agent in a human or non-human animal. Dated this 11th day of September 2003. Starpharma Limited By its Patent Attorneys Davies Collison Cave *o